WO2018183685A1 - Methods of regulating gene expression in a cell - Google Patents
Methods of regulating gene expression in a cell Download PDFInfo
- Publication number
- WO2018183685A1 WO2018183685A1 PCT/US2018/025154 US2018025154W WO2018183685A1 WO 2018183685 A1 WO2018183685 A1 WO 2018183685A1 US 2018025154 W US2018025154 W US 2018025154W WO 2018183685 A1 WO2018183685 A1 WO 2018183685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactobacillus
- nucleic acid
- transcriptional repressor
- promoter
- lactic acid
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000001105 regulatory effect Effects 0.000 title description 18
- 230000027455 binding Effects 0.000 claims abstract description 150
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 119
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 99
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 82
- 239000004098 Tetracycline Substances 0.000 claims abstract description 65
- 229960002180 tetracycline Drugs 0.000 claims abstract description 65
- 229930101283 tetracycline Natural products 0.000 claims abstract description 65
- 235000019364 tetracycline Nutrition 0.000 claims abstract description 65
- 150000003522 tetracyclines Chemical class 0.000 claims abstract description 65
- 230000001939 inductive effect Effects 0.000 claims abstract description 42
- 108010034634 Repressor Proteins Proteins 0.000 claims abstract description 39
- 102000009661 Repressor Proteins Human genes 0.000 claims abstract description 39
- 239000013598 vector Substances 0.000 claims abstract description 39
- 108091006107 transcriptional repressors Proteins 0.000 claims description 111
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 109
- 238000013518 transcription Methods 0.000 claims description 72
- 230000035897 transcription Effects 0.000 claims description 72
- 101150024821 tetO gene Proteins 0.000 claims description 70
- 241000186660 Lactobacillus Species 0.000 claims description 67
- 230000001580 bacterial effect Effects 0.000 claims description 65
- 102000004169 proteins and genes Human genes 0.000 claims description 56
- 239000004310 lactic acid Substances 0.000 claims description 54
- 235000014655 lactic acid Nutrition 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 101100126165 Escherichia coli (strain K12) intA gene Proteins 0.000 claims description 44
- 101100502851 Shigella flexneri fkbP2 gene Proteins 0.000 claims description 44
- 101150074641 fkpB gene Proteins 0.000 claims description 44
- 101150076332 slpA gene Proteins 0.000 claims description 44
- 229940039696 lactobacillus Drugs 0.000 claims description 42
- 239000011230 binding agent Substances 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 230000002103 transcriptional effect Effects 0.000 claims description 19
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 10
- 102000034287 fluorescent proteins Human genes 0.000 claims description 7
- 108091006047 fluorescent proteins Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108091033409 CRISPR Proteins 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 108700008625 Reporter Genes Proteins 0.000 claims description 5
- 230000003281 allosteric effect Effects 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 241000186716 Lactobacillus agilis Species 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 241001561398 Lactobacillus jensenii Species 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 241000206594 Carnobacterium Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000186717 Lactobacillus acetotolerans Species 0.000 claims description 2
- 241000110061 Lactobacillus acidifarinae Species 0.000 claims description 2
- 241000028630 Lactobacillus acidipiscis Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 241001507052 Lactobacillus algidus Species 0.000 claims description 2
- 241000186715 Lactobacillus alimentarius Species 0.000 claims description 2
- 241000905759 Lactobacillus alvei Species 0.000 claims description 2
- 241000757132 Lactobacillus alvi Species 0.000 claims description 2
- 241001647783 Lactobacillus amylolyticus Species 0.000 claims description 2
- 241000186714 Lactobacillus amylophilus Species 0.000 claims description 2
- 241000168643 Lactobacillus amylotrophicus Species 0.000 claims description 2
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 2
- 241000186712 Lactobacillus animalis Species 0.000 claims description 2
- 241000433459 Lactobacillus animata Species 0.000 claims description 2
- 241000316282 Lactobacillus antri Species 0.000 claims description 2
- 241001370007 Lactobacillus apinorum Species 0.000 claims description 2
- 241000905791 Lactobacillus apis Species 0.000 claims description 2
- 241000954248 Lactobacillus apodemi Species 0.000 claims description 2
- 241000861652 Lactobacillus aquaticus Species 0.000 claims description 2
- 241000186711 Lactobacillus aviarius Species 0.000 claims description 2
- 241000159904 Lactobacillus backii Species 0.000 claims description 2
- 241000186723 Lactobacillus bifermentans Species 0.000 claims description 2
- 241000632581 Lactobacillus bombi Species 0.000 claims description 2
- 241000088816 Lactobacillus bombicola Species 0.000 claims description 2
- 241000631121 Lactobacillus brantae Species 0.000 claims description 2
- 240000001929 Lactobacillus brevis Species 0.000 claims description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 2
- 241000222984 Lactobacillus brevisimilis Species 0.000 claims description 2
- 241000186679 Lactobacillus buchneri Species 0.000 claims description 2
- 241000208559 Lactobacillus cacaonum Species 0.000 claims description 2
- 241000489238 Lactobacillus camelliae Species 0.000 claims description 2
- 241000176719 Lactobacillus capillatus Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000272787 Lactobacillus catenefornis Species 0.000 claims description 2
- 241000902616 Lactobacillus ceti Species 0.000 claims description 2
- 241001061980 Lactobacillus coleohominis Species 0.000 claims description 2
- 241001275379 Lactobacillus colini Species 0.000 claims description 2
- 241001468197 Lactobacillus collinoides Species 0.000 claims description 2
- 241000933456 Lactobacillus composti Species 0.000 claims description 2
- 241000838743 Lactobacillus concavus Species 0.000 claims description 2
- 241000186842 Lactobacillus coryniformis Species 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000861211 Lactobacillus crustorum Species 0.000 claims description 2
- 241000707676 Lactobacillus curieae Species 0.000 claims description 2
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 2
- 241000500356 Lactobacillus dextrinicus Species 0.000 claims description 2
- 241000790171 Lactobacillus diolivorans Species 0.000 claims description 2
- 241000976279 Lactobacillus equi Species 0.000 claims description 2
- 241001305661 Lactobacillus equicursoris Species 0.000 claims description 2
- 241001026944 Lactobacillus equigenerosi Species 0.000 claims description 2
- 241000208558 Lactobacillus fabifermentans Species 0.000 claims description 2
- 241000268611 Lactobacillus faecis Species 0.000 claims description 2
- 241000541936 Lactobacillus faeni Species 0.000 claims description 2
- 241001016125 Lactobacillus floricola Species 0.000 claims description 2
- 241001457879 Lactobacillus florum Species 0.000 claims description 2
- 241000197632 Lactobacillus formosensis Species 0.000 claims description 2
- 241000015236 Lactobacillus fornicalis Species 0.000 claims description 2
- 241000186839 Lactobacillus fructivorans Species 0.000 claims description 2
- 241001493843 Lactobacillus frumenti Species 0.000 claims description 2
- 241000370757 Lactobacillus fuchuensis Species 0.000 claims description 2
- 241000859743 Lactobacillus furfuricola Species 0.000 claims description 2
- 241000319245 Lactobacillus futsaii Species 0.000 claims description 2
- 241000509544 Lactobacillus gallinarum Species 0.000 claims description 2
- 241000316283 Lactobacillus gastricus Species 0.000 claims description 2
- 241000950383 Lactobacillus ghanensis Species 0.000 claims description 2
- 241000968129 Lactobacillus gigeriorum Species 0.000 claims description 2
- 241001585829 Lactobacillus ginsenosidimutans Species 0.000 claims description 2
- 241000480414 Lactobacillus gorillae Species 0.000 claims description 2
- 241000866684 Lactobacillus graminis Species 0.000 claims description 2
- 241000054537 Lactobacillus guizhouensis Species 0.000 claims description 2
- 241001089518 Lactobacillus halophilus Species 0.000 claims description 2
- 241000111368 Lactobacillus hammesii Species 0.000 claims description 2
- 241000383778 Lactobacillus hamsteri Species 0.000 claims description 2
- 241000925032 Lactobacillus harbinensis Species 0.000 claims description 2
- 241000914114 Lactobacillus hayakitensis Species 0.000 claims description 2
- 241000762075 Lactobacillus heilongjiangensis Species 0.000 claims description 2
- 241001370013 Lactobacillus helsingborgensis Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241000629513 Lactobacillus herbarum Species 0.000 claims description 2
- 241001147748 Lactobacillus heterohiochii Species 0.000 claims description 2
- 241000186685 Lactobacillus hilgardii Species 0.000 claims description 2
- 241001204812 Lactobacillus hokkaidonensis Species 0.000 claims description 2
- 241000968140 Lactobacillus hominis Species 0.000 claims description 2
- 241001468190 Lactobacillus homohiochii Species 0.000 claims description 2
- 241000453537 Lactobacillus iatae Species 0.000 claims description 2
- 241001324870 Lactobacillus iners Species 0.000 claims description 2
- 241001343376 Lactobacillus ingluviei Species 0.000 claims description 2
- 241000905760 Lactobacillus insectis Species 0.000 claims description 2
- 241000594516 Lactobacillus insicii Species 0.000 claims description 2
- 241001302801 Lactobacillus intermedius Species 0.000 claims description 2
- 241001640457 Lactobacillus intestinalis Species 0.000 claims description 2
- 241001534330 Lactobacillus iwatensis Species 0.000 claims description 2
- 241001290620 Lactobacillus ixorae Species 0.000 claims description 2
- 241001147723 Lactobacillus japonicus Species 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000316281 Lactobacillus kalixensis Species 0.000 claims description 2
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 claims description 2
- 241001468191 Lactobacillus kefiri Species 0.000 claims description 2
- 241001369794 Lactobacillus kimbladii Species 0.000 claims description 2
- 241001108870 Lactobacillus kimchicus Species 0.000 claims description 2
- 241000795439 Lactobacillus kimchiensis Species 0.000 claims description 2
- 241000191683 Lactobacillus kisonensis Species 0.000 claims description 2
- 241000674808 Lactobacillus kitasatonis Species 0.000 claims description 2
- 241001167943 Lactobacillus koreensis Species 0.000 claims description 2
- 241001370012 Lactobacillus kullabergensis Species 0.000 claims description 2
- 241001339775 Lactobacillus kunkeei Species 0.000 claims description 2
- 241000905789 Lactobacillus larvae Species 0.000 claims description 2
- 241001134654 Lactobacillus leichmannii Species 0.000 claims description 2
- 241000751202 Lactobacillus letivazi Species 0.000 claims description 2
- 241000520745 Lactobacillus lindneri Species 0.000 claims description 2
- 241000751214 Lactobacillus malefermentans Species 0.000 claims description 2
- 241000186851 Lactobacillus mali Species 0.000 claims description 2
- 241000016642 Lactobacillus manihotivorans Species 0.000 claims description 2
- 241001370011 Lactobacillus mellifer Species 0.000 claims description 2
- 241001369797 Lactobacillus mellis Species 0.000 claims description 2
- 241001369796 Lactobacillus melliventris Species 0.000 claims description 2
- 241000890979 Lactobacillus micheneri Species 0.000 claims description 2
- 241000414465 Lactobacillus mindensis Species 0.000 claims description 2
- 241001460205 Lactobacillus mixtipabuli Species 0.000 claims description 2
- 241001104724 Lactobacillus mobilis Species 0.000 claims description 2
- 241000394636 Lactobacillus mucosae Species 0.000 claims description 2
- 241000962439 Lactobacillus mudanjiangensis Species 0.000 claims description 2
- 241000186871 Lactobacillus murinus Species 0.000 claims description 2
- 241001635183 Lactobacillus nagelii Species 0.000 claims description 2
- 241000468580 Lactobacillus namurensis Species 0.000 claims description 2
- 241000938545 Lactobacillus nantensis Species 0.000 claims description 2
- 241000645171 Lactobacillus nasuensis Species 0.000 claims description 2
- 241000962388 Lactobacillus nenjiangensis Species 0.000 claims description 2
- 241001097694 Lactobacillus nodensis Species 0.000 claims description 2
- 241000176718 Lactobacillus odoratitofui Species 0.000 claims description 2
- 241000908019 Lactobacillus oeni Species 0.000 claims description 2
- 241001150383 Lactobacillus oligofermentans Species 0.000 claims description 2
- 241000929684 Lactobacillus oryzae Species 0.000 claims description 2
- 241000191684 Lactobacillus otakiensis Species 0.000 claims description 2
- 241000024618 Lactobacillus ozensis Species 0.000 claims description 2
- 241000216456 Lactobacillus panis Species 0.000 claims description 2
- 241000692795 Lactobacillus pantheris Species 0.000 claims description 2
- 241001105994 Lactobacillus parabrevis Species 0.000 claims description 2
- 241001643453 Lactobacillus parabuchneri Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 241000972176 Lactobacillus paracollinoides Species 0.000 claims description 2
- 241001643449 Lactobacillus parakefiri Species 0.000 claims description 2
- 241001647418 Lactobacillus paralimentarius Species 0.000 claims description 2
- 241000866650 Lactobacillus paraplantarum Species 0.000 claims description 2
- 241000351429 Lactobacillus pasteurii Species 0.000 claims description 2
- 241000442265 Lactobacillus paucivorans Species 0.000 claims description 2
- 241000186684 Lactobacillus pentosus Species 0.000 claims description 2
- 241001448603 Lactobacillus perolens Species 0.000 claims description 2
- 241000590395 Lactobacillus plajomi Species 0.000 claims description 2
- 241000488807 Lactobacillus pobuzihii Species 0.000 claims description 2
- 241001495404 Lactobacillus pontis Species 0.000 claims description 2
- 241000220680 Lactobacillus psittaci Species 0.000 claims description 2
- 241000191682 Lactobacillus rapi Species 0.000 claims description 2
- 241000692139 Lactobacillus rennini Species 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 241000673991 Lactobacillus rodentium Species 0.000 claims description 2
- 241000602084 Lactobacillus rossiae Species 0.000 claims description 2
- 241000186870 Lactobacillus ruminis Species 0.000 claims description 2
- 241000318646 Lactobacillus saerimneri Species 0.000 claims description 2
- 241000186612 Lactobacillus sakei Species 0.000 claims description 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 2
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 claims description 2
- 235000013864 Lactobacillus sanfrancisco Nutrition 0.000 claims description 2
- 241000241526 Lactobacillus saniviri Species 0.000 claims description 2
- 241001424195 Lactobacillus satsumensis Species 0.000 claims description 2
- 241000915257 Lactobacillus secaliphilus Species 0.000 claims description 2
- 241000241523 Lactobacillus senioris Species 0.000 claims description 2
- 241000024101 Lactobacillus senmaizukei Species 0.000 claims description 2
- 241000186867 Lactobacillus sharpeae Species 0.000 claims description 2
- 241000364915 Lactobacillus shenzhenensis Species 0.000 claims description 2
- 241000769541 Lactobacillus sicerae Species 0.000 claims description 2
- 241000894443 Lactobacillus silagei Species 0.000 claims description 2
- 241000755777 Lactobacillus siliginis Species 0.000 claims description 2
- 241001004348 Lactobacillus similis Species 0.000 claims description 2
- 241000962441 Lactobacillus songhuajiangensis Species 0.000 claims description 2
- 241001599932 Lactobacillus spicheri Species 0.000 claims description 2
- 241000758161 Lactobacillus sucicola Species 0.000 claims description 2
- 241001643448 Lactobacillus suebicus Species 0.000 claims description 2
- 241000191665 Lactobacillus sunkii Species 0.000 claims description 2
- 241000390527 Lactobacillus taiwanensis Species 0.000 claims description 2
- 241000489237 Lactobacillus thailandensis Species 0.000 claims description 2
- 241000692136 Lactobacillus tucceti Species 0.000 claims description 2
- 241000316280 Lactobacillus ultunensis Species 0.000 claims description 2
- 241000908018 Lactobacillus uvarum Species 0.000 claims description 2
- 241000751212 Lactobacillus vaccinostercus Species 0.000 claims description 2
- 241000186783 Lactobacillus vaginalis Species 0.000 claims description 2
- 241000186865 Lactobacillus vermiforme Species 0.000 claims description 2
- 241000828228 Lactobacillus vespulae Species 0.000 claims description 2
- 241000692127 Lactobacillus vini Species 0.000 claims description 2
- 241000127265 Lactobacillus wasatchensis Species 0.000 claims description 2
- 241000617441 Lactobacillus xiangfangensis Species 0.000 claims description 2
- 241000044168 Lactobacillus yonginensis Species 0.000 claims description 2
- 241000577554 Lactobacillus zeae Species 0.000 claims description 2
- 241000110060 Lactobacillus zymae Species 0.000 claims description 2
- 241000192132 Leuconostoc Species 0.000 claims description 2
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 2
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 2
- 241000202223 Oenococcus Species 0.000 claims description 2
- 241000192001 Pediococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000500334 Tetragenococcus Species 0.000 claims description 2
- 241000207194 Vagococcus Species 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 239000006356 lactobacillus kefiranofaciens Substances 0.000 claims description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 claims 37
- 101710163270 Nuclease Proteins 0.000 claims 11
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 5
- 241001112724 Lactobacillales Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000013611 chromosomal DNA Substances 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 97
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 66
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 30
- 108020004707 nucleic acids Proteins 0.000 description 30
- 230000006870 function Effects 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 238000013461 design Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000011144 upstream manufacturing Methods 0.000 description 15
- 108091035707 Consensus sequence Proteins 0.000 description 11
- 230000028327 secretion Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000004568 DNA-binding Effects 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 101150061166 tetR gene Proteins 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 5
- 108010053775 Nisin Proteins 0.000 description 5
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004309 nisin Substances 0.000 description 5
- 235000010297 nisin Nutrition 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001718 repressive effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- -1 HCV-CSA Proteins 0.000 description 4
- 241000186604 Lactobacillus reuteri Species 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108020004418 ribosomal RNA Proteins 0.000 description 4
- 238000012772 sequence design Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101100119095 Enterococcus faecalis (strain ATCC 700802 / V583) ermB gene Proteins 0.000 description 3
- 241000495778 Escherichia faecalis Species 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 244000057717 Streptococcus lactis Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 101100006766 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) clpX gene Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101710184697 S-layer protein A Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000008860 allosteric change Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 101150113622 clpC gene Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100325906 Bacillus subtilis (strain 168) ganA gene Proteins 0.000 description 1
- 101100257434 Bacillus subtilis spaC gene Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102100038326 Beta-defensin 4A Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241000701520 Corticoviridae Species 0.000 description 1
- 241000702221 Cystoviridae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 101100157003 Escherichia coli (strain K12) xylF gene Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000701367 Fuselloviridae Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000702394 Inoviridae Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000724748 Lactobacillus phage phiadh Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 108010003571 Nut Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150054516 PRD1 gene Proteins 0.000 description 1
- 241000701369 Plasmaviridae Species 0.000 description 1
- 241000702072 Podoviridae Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100459905 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NCP1 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 241000701521 Tectiviridae Species 0.000 description 1
- 101100111413 Thermoanaerobacter pseudethanolicus (strain ATCC 33223 / 39E) lacZ gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 108010007389 Trefoil Factors Proteins 0.000 description 1
- 108010064721 Type I Secretion Systems Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YFHLIDBAPTWLGU-CTKMSOPVSA-N dermaseptin Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C1=CN=CN1 YFHLIDBAPTWLGU-CTKMSOPVSA-N 0.000 description 1
- 108090000454 dermaseptin Proteins 0.000 description 1
- 229940049701 dermaseptin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940099052 fuzeon Drugs 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 101150086432 lacA gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 101150107585 tetA gene Proteins 0.000 description 1
- 101150015970 tetM gene Proteins 0.000 description 1
- 101150014444 tetS gene Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 101150033567 xylT gene Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates in general to methods of regulating gene expression in a cell.
- Lactobacilli are important industrial microbes in the dairy industry and are heavily targeted for use in vivo due to their FDA status as a generally regarded as safe (GRAS) probiotic organism.
- GRAS safe
- Inducible expression systems are usually based on "borrowing" native regulation responsive to their cognate sugar activators. While several inducible promoters have been tried in Lactobacilli, all suffer from high levels of basal leakage because the rich media formulations required for the growth of most species already contain non-trivial levels of the inducing sugar. See T. Duong et al. Construction of vectors for inducible and constitutive gene expression in Lactobacillus. Microb Biotech.
- NICE nisin-controlled gene expression
- pSIP nisin-controlled gene expression
- nisin-controlled expression system in Lactobacillus plantarum: a tool to study in vivo biological effects.
- both nisin and sakacin are bacteriocins, and their antibiotic effects may be deleterious to the host species.
- a lactic acid bacterial cell includes a constitutive promoter sequence that has been altered to include one or more transcription repressor protein binding sites.
- the altered constitutive promoter sequence is operable when the one or more transcription repressor protein binding sites are unbound by a corresponding transcription repressor protein. According to one aspect, insertion of the one or more transcription repressor protein binding sites does not alter or significantly alter the ability of the constitutive promoter sequence to operate or function. Accordingly, transcription by the cell of the target nucleic acid sequence proceeds.
- a transcription repressor protein is provided to the cell, such as by expression of a foreign nucleic acid sequence encoding for the corresponding transcription repressor protein, the transcription repressor protein binds to the transcription repressor protein binding site and transcription of the target nucleic acid sequence is repressed.
- the transcription repressor protein may be allosteric.
- the binding agent When a cognate binding agent is introduced to the cell, the binding agent binds to the transcription repressor protein causing an allosteric change which removes the transcription repressor protein from the transcription repressor protein binding site or otherwise prevents or inhibits binding of the transcription repressor protein to the transcription repressor protein binding site. As a result, transcription of the target nucleic acid sequence is activated.
- the nucleic acid sequence within the cell that includes the promoter sequence and the one or more transcription repressor binding sites may be referred to as an agent-responsive element to the extent that the altered promoter sequence (when the transcription repressor protein is bound to the transcription repressor protein binding site) is responsive to the binding agent, i.e., transcription is activated.
- lactic acid bacteria are genetically modified to include a tetracycline-responsive element operably linked to a target nucleic acid sequence, such that the tetracycline-responsive element is inducible in the presence of tetracycline to initiate transcription of the target nucleic acid sequence into a corresponding mRNA and translation into a corresponding amino acid sequence.
- Methods of making lactic acid bacterial cells including an inducible system for control of gene expression based on agent-responsive promoters or elements, such as tetracycline-responsive promoters, genetic constructs and the use of such cells are also disclosed.
- a method for controlling the expression of one or more proteins by a lactic acid bacterial cell within a subject including introducing into the subject a lactic acid bacterial cell or population of lactic acid bacterial cells including (1) an endogenous constitutive promoter sequence modified to include one or more transcriptional repressor protein binding sites, wherein the promoter sequence is operably linked to one or more target nucleic acid sequences encoding the one or more proteins; and (2) exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and providing the subject with a cognate binding agent which binds to the one or more transcriptional repressor proteins to activate the promoter and induce transcription of the one or more target nucleic acid sequences.
- Fig. 1 depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. rhamnosus GG.
- Fig. 2 depicts data of gene expression of L. delbrueckii 2038.
- Fig. 3 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus delbruckii.
- Fig. 4 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus rhamnosus GG.
- Fig. 5 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus gasseri.
- Fig. 6 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus Phages.
- Fig. 7 depicts the nucleic acid sequence design for Variant 1 (SEQ ID NO: 24).
- Fig. 8 depicts the nucleic acid sequence design for Variant 2 (SEQ ID NO: 25).
- Fig. 9 depicts the nucleic acid sequence design for Variant 3 (SEQ ID NO: 26).
- Fig. 10 depicts the nucleic acid sequence design for Variant 4 (SEQ ID NO: 27).
- Fig. 11 depicts in schematic minimum free energy mRNA structural folding predictions for various mRNA structures.
- Fig. 12 depicts fluorescence data of relative expression strengths for the promoter for the ribosomal RNA 3-a from L. plantarum and slpA.
- Fig. 13 depicts data demonstrating that slpA with a deletion successfully drives repressor function across a dynamic range of 10 6 in EL coli, when paired with slpA-tetO variant 2.
- Fig. 14 depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. gasseri.
- Fig. IS depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. gasseri, with a hybrid promoter variant.
- Fig. 16 depicts data showing suppressed leakage of an aTc-inducible slpA promoter variant modified to more closely resemble the general tetO binding site sequence space of PltetO.
- Fig. 17 is a gel image of an experiment showing expression of HisTagged, anti-HTV (gpl20) camelid nanobody (J3-VHH) using an aTc-inducible expression cassette encoding J3- VHH secretion.
- embodiments of the present disclosure are intended to utilize the particular sequences disclosed herein and sequences having at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to the particular sequence disclosed herein.
- the present disclosure provides a lactic acid bacterial cell including a first exogenous nucleic acid sequence comprising an agent-responsive element operably linked to a target nucleic acid sequence, such that the agent-responsive element is inducible in the presence of the agent to initiate transcription of the target nucleic acid sequence into a corresponding mRNA and translation into a corresponding amino acid sequence.
- the agent bonds to a transcriptional repressor protein which may or may not be bound to a transcriptional repressor protein binding site to cause an allosteric or conformational change to the transcriptional repressor protein thereby releasing the transcriptional repressor protein from the transcriptional repressor protein binding site or thereby preventing binding of the transcriptional repressor protein to the transcriptional repressor protein binding site, thereby allowing transcription of the target nucleic acid sequence.
- the agent-responsive element includes a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins, wherein the constitutive promoter sequence within the agent-responsive element is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins.
- the agent-responsive element includes a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites and wherein the lactic acid bacterial cell further includes an exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and wherein, the agent activates the promoter, i.e. agent-responsive promoter or element, and induces transcription of the target nucleic acid sequence.
- aspects of the present disclosure include the genetic modification of a cell to include foreign genetic material which can then be expressed by the cell.
- the cell may be modified to include any other genetic material or elements useful in the expression of a nucleic acid sequence.
- Foreign genetic elements may be introduced or provided to a cell using methods known to those of skill in the art.
- a genetically modified cell encompasses lactic acid bacterial cells that have been engineered to include an episomal or expression vector or otherwise incorporate a nucleic acid sequence, such as for example in the genome or the cell. Cells and techniques for cellular transformation are well known in the art (see e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor (1989)).
- Embodiments of the present disclosure provide a genetically modified lactic acid bacterial cell including a first nucleic acid sequence comprising a first promoter operably linked to a DNA binding molecule such as a tetracycline repressor gene coding sequence, and a second nucleic acid sequence comprising a second promoter operably linked to a target nucleic acid sequence such as a coding sequence of a gene of interest wherein the second promoter is modified to include one or more DNA binding molecule binding sites, such as tetracycline repressor protein binding sites.
- Embodiments of the present disclosure are directed to methods of making a tetracycline inducible expression system in a lactic acid bacterial cell.
- the cell is genetically modified to include a first nucleic acid sequence comprising a first promoter operably linked to a tetracycline repressor gene coding sequence, and a second nucleic acid sequence comprising a second promoter operably linked to a coding sequence of a gene of interest wherein the second promoter is modified to include one or more tetracycline repressor protein binding sites.
- the first promoter drives constitutive expression of a tetracycline repressor.
- the second promoter regulates the expression of a gene of interest in response to tetracycline induction.
- Embodiments of the present disclosure provide for a first nucleic acid sequence including a first promoter operably linked to a tetracycline repressor gene coding sequence.
- the first promoter can be any promoter that is operable in a lactic acid bacterial cell.
- the first promoter can drive constitutive expression of the tet repressor.
- the first nucleic acid sequence is represented by a sequence having at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 1 and the first promoter is an L. plantarum ribosomal RNA promoter.
- Embodiments of the present disclosure provide for a second nucleic acid sequence including a second promoter operably linked to a coding sequence of a gene of interest wherein the promoter is modified to include one or more tetracycline repressor protein binding sites.
- the second promoter is inducible by an inducing agent.
- the promoter is inducible by tetracycline or its analogs or functional equivalents.
- the second promoter is operable in lactic acid bacterial cells.
- the second promoter is an slpA promoter.
- the second promoter is modified to include one or more tetracycline repressor protein binding sites so that tight control of gene expression in the respective prokaryotic or eukaryotic cell can be achieved.
- the modified promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 2 or SEQ ID NO: 4.
- Embodiments of the present disclosure provide an expression vector including a nucleic acid sequence including a promoter operably linked to a coding sequence of a gene of interest wherein the promoter is modified to include one or more tetracycline repressor protein binding sites.
- a polynucleotide sequence can be operably linked to the promoter.
- the polynucleotide sequence may be a polynucleotide sequence encoding a gene, an antisense polynucleotide, a ribozyme, a fusion protein, a polynucleotide encoding an antibody, or therapeutic protein etc.
- Cells according to the present disclosure include lactic acid bacterial cells.
- Exemplary lactic acid bacterial cells include bacterial cells within the order LactobacilMes.
- bacterial cells include bacterial cells from the genus Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Carnobacterium, Enterococcus, Oenococcus, Tetragenococcus, Vagococcus, or Weisella.
- bacterial cells include bacterial cells from the species Lactobacillus acetotolerans, Lactobacillus acidifarinae, Lactobacillus acidipiscis, Lactobacillus acidophilus, Lactobacillus agilis,Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus alvei, Lactobacillus alvi, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylotrophicus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus animata, Lactobacillus antri, Lactobacillus apinorum, Lactobacillus apis, Lactobacillus apodemi, Lactobacillus aquaticus, Lactobacillus aviarius, Lactobacillus backii, Lactobacillus bifermentans, Lactobacillus bombi, Lactobacillus bomb
- the recombinant expression vector may include the agent-responsive promoter or element as described herein.
- the recombinant expression vector may include the nucleic acid encoding the transcriptional repression protein.
- the recombinant expression vector may include the altered or modified promoter sequence that includes one or more transcriptional repression protein binding sites.
- host cell and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- the disclosure provides an agent-responsive element.
- the agent responsive element includes one or more of a constitutive promoter sequence, which may be endogenous or exogenous, and one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins.
- the constitutive promoter sequences may be modified or altered to include the one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins.
- the constitutive promoter sequence combined with one or more exogenous transcriptional repressor protein binding sites is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins.
- the presence of the one or more exogenous transcriptional repressor protein binding sites may not inhibit the transcription of a target nucleic acid sequence as activated by the constitutive promoter sequence.
- the one or more exogenous transcriptional repressor protein binding sites may be placed upstream of the constitutive promoter sequence or within the constitutive promoter sequence.
- the agent as described herein, is an entity that binds to the transcriptional repressor protein in a manner to inhibit binding of the transcriptional repressor protein to the transcriptional repressor protein binding site. When binding of the transcriptional repressor protein to the transcriptional repressor protein binding site is inhibited, transcription of the target nucleic acid sequence is promoted or activated through the constitutive promoter.
- a constitutive promoter sequence is modified to include one or more transcriptional repressor protein binding sites.
- the promoter sequence may be referred to as an altered promoter sequence or a modified promoter sequence.
- the transcriptional repressor protein binding site has a corresponding transcriptional repressor protein that binds to the transcriptional repressor protein binding site.
- the transcriptional repressor protein has a cognate binding partner that when bound to the transcriptional repressor protein inhibits binding of the transcriptional repressor protein to the transcriptional repressor protein binding site by way of allosteric change of the transcriptional repressor protein or steric hindrance or other mechanism of inhibition.
- An exemplary agent-induction system is the tetracycline induction system which has been used extensively in bacterial, fungal, plant, and mammalian systems. See J.L. Ramos et al. The TetR family of transcriptional repressors. Microbiol Mol Biol Rev. 2005 Jun;69(2):326-56; E. Gari et al. A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae. Yeast. 1997 Jul;13(9):837-48; P. Weinmann et al. A chimeric transactivator allowes tetracycline-responsive gene expression in whole plants. Plant J.
- a tetracycline-regulatable promoter system with tetracycline being the agent that induces transcription, is exemplary because of its ability to facilitate tight regulation and exhibit superior dynamic range of up to 5000-fold (see R. Lutz & H. Bujard.
- the agent- responsive element and the agent are exemplary in their ability to exhibit, in most hosts of interest, little to no crosstalk between the system and host genetics or metabolism. Heterologous gene expression may thus be more reliably controlled by the experimenter.
- a tetracycline-regulatable promoter system is particularly exemplary.
- tetracycline-regulatable promoter system also enables tetracycline or anhydrous tetracycline (aTc) induction's use in vivo.
- aTc tetracycline or anhydrous tetracycline
- the promoter is endogenous and is a strong constitutive promoter with a longer promoter sequence into which operator boxes may be placed to control and regulate the promoter. Longer promoter sequences allow operator boxes to be inserted and not abrogate promoter ability but also to stop promoter ability when the transcriptional repressor protein binds.
- repressor or “transcriptional repressor protein” refers to a molecule capable of inhibiting the expression of a particular nucleic acid sequence, such as a gene, from a promoter. In effect, the molecule "represses” the expression of the gene from its promoter.
- repressor systems will readily be recognized by those of skill in the art based on the present disclosure and which include a DNA binding site also referred to as a transcriptional repressor protein binding site or operator sequence and its corresponding binding partner also referred to as a transcriptional repressor protein.
- the corresponding binding partner When the DNA binding site is included into a DNA sequence in a cell and the corresponding binding partner is provided to the cell, the corresponding binding partner binds to the DNA binding site.
- a system can be used to inhibit transcription when operably linked to a promoter sequence.
- Such a system can be included into a constitutive promoter sequence to transform the constitutive promoter sequence into an inducible promoter sequence.
- the binding of the corresponding binding partner to the DNA binding site within a promoter sequence inhibits transcription of a target nucleic acid sequence operatively connected or linked to the promoter sequence.
- the constitutive promoter sequence begins transcription of the target nucleic acid sequence.
- an agent that binds to the transcriptional repressor protein causing a conformational change in the transcriptional repressor protein thereby rendering it unable to bind to the transcriptional repressor protein binding site.
- the transcriptional repressor protein is allosteric insofar as it can change structure or form when bound by an agent. In this manner, repressor dimerization and function may be disrupted.
- An agent may also inhibit binding of the transcriptional repressor protein through steric hindrance or other methods.
- Transcriptional repressor proteins and their cognate binding sites are known to those of skill in the art and such as the TetR/tetO system, LacR/lacO or TreR/treO (lactose and trehalose controlled repression).
- TetR tet repressor
- the tet repressor (TetR) is a protein that represses gene transcription of the tet operon upon binding to its cognate tet operator sequences tetO (tet binding sites) within the operon promoter.
- TetR tet repressor
- the TetR/tetO system is said to be a tetracycline responsive system insofar as tetracycline, anhydrous tetracycline or suitable derivatives of tetracycline may prevent binding of the tetracycline repressor to the tet operator sequences.
- Additional agent-responsive promoter systems include metabolite responsive systems such as metabolite-controlled operator boxes paired with their corresponding repressor such as LacR/lacO & TreR/treO (lactose and trehalose controlled repression).
- Additional repressor systems exist which are based on binding agents such as glucose, mannose, fructose, galactose, sucrose, raffinose, maltose, arabinose, ribose, sorbose, rhamnose, xylose which inhibit binding of a cognate transcriptional repressor protein thereby activating traqnscription.
- Such repressor systems may be included within any promoter sequence, such as slpA.
- a cell is genetically modified to include one or more exogenous nucleic acids encoding for a transcriptional repressor protein and wherein the cell includes the cognate transcriptional repressor protein binding site.
- a binding agent cognate to the transcriptional repressor protein is also provided.
- the cell may also be genetically modified to include one or more exogenous nucleic acid sequences including one or more transcriptional repressor protein binding sites. Transcriptional repressor proteins and their corresponding or cognate binding agents are known to those of skill in the art and include those listed in Table 1 below.
- transcriptional repressors and their corresponding binding agents are exemplary only and that one of skill in the art can readily identify additional transcriptional repressors and their corresponding binding agents for use in the present disclosure. Aside from the TetR family of transcriptional repressors, any member of the main bacterial transcriptional repressor families could be similarly implemented.
- This list includes members of the ArgR, AsnC/LrP, DeoR, GalR LacI, GntR, IclR, LysR, MerR, MetJ, ModE, PadR and XRE families, not excluding other groups or subgroups of transcriptional regulators from bacterial, phagic or mammalian origin directly used or repurposed for their application in Lactobacilli.
- Transcriptional repressors and/or binding agents may be natural or synthetic.
- One of skill can also design synthetic transcriptional repressors to bind to natural or non-natural cognate nucleic acid sequences and which may further bind natural or non-natural binding agents using methods known to those of skill in the art.
- the transformed cell is intended to express the transcriptional repressor under suitable conditions. Methods described herein can be used to insert the nucleic acids into the genome of the cells that are responsible for production of transcriptional repressors.
- the transformed, recombinant cell expresses the transcriptional repressor protein which regulates production of a target nucleic acid, for example, by binding to transcriptional repressor protein binding site within a promoter thereby inhibiting transcription of the target nucleic acid.
- the transcriptional repressor protein when expressed, prevents the cell from expressing the target nucleic acid, either by blocking the expression (i.e. a repressor) of the target nucleic acid unless the transcriptional repressor protein is bound by the binding agent, which leads to target nucleic acid expression.
- the repressor protein blocks transcription of the reporter gene by binding as an oligomer to a region of DNA 5' to the reporter gene unless the desired binding agent binds the repressor thereby disrupting the oligomeric behavior and thus frequently preventing the effective binding of the complex to its cognate operator sequences.
- the transformed, recombinant cell is provided with a binding agent which binds to the transcription repressor protein in a manner to promote production of the peptide, polypeptide or amino acid sequence corresponding to the target nucleic acid sequence.
- the transcription repressor protein prevents transcription of the target nucleic acid in the absence of the binding agent.
- Target nucleic acid sequences maybe of any sequences desired to be transcribed.
- Target nucleic acid sequences include those that encode for therapeutic proteins, diagnostic proteins, reporter proteins, genes or enzymes.
- gene refers to the nucleic acid sequence that undergoes transcription as the result of promoter activity.
- a gene may code for a particular protein or, alternatively, code for an RNA sequence that is of interest in itself, e.g. because it acts as an antisense inhibitor.
- Therapeutic proteins envisioned herein include proteins, such as endogenous proteins, associated with probiotic function (e.g. LGG p40, spaC), antibodies (including IgG, IgE, IgA, scFv and camlid antibodies - that target infectious agents, or host cell-surface proteins and antibody Fc), antimicrobial peptides of mammalian, viral, and bacterial origin (e.g. collistin, caerin, dermaseptin, LL-37, HBD-2) antiviral peptides (e.g. HCV-CSA, Fuzeon), cytokines (e.g. IL-10), allergens (e.g. pollen, nut proteins), worm protein (e.g. hookworm protein), trefoil factor, dietary enzymes, mucin binding proteins (e.g. intJ, GroEL), invasins, antitoxins or any antigen derived from an infectious agent delivered as a vaccination target.
- probiotic function e.g. LGG p40, spaC
- Diagnostic proteins envisioned herein include antibodies that also can be used as diagnostic sensors, reactive oxygen species sensors or temperature sensors.
- the target nucleic acid sequence or downstream gene is a detectable moiety or reporter, such as a fluorescent moiety, such as GFP, that can be detected by fluorimetry, for example.
- a detectable moiety is a reporter protein.
- Reporter proteins envisioned herein include fluorescent proteins, luminescent proteins, enzymatic reporters such as GusA or PepN.
- Aspects of the methods described herein may make use of epitope tags and reporter gene sequences as detectable moieties.
- epitope tags include histidine (His) tags, VS tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
- reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, maltose binding protein, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
- GST glutathione-S-transferase
- HRP horseradish peroxidase
- CAT chloramphenicol acetyltransferase
- beta-galactosidase beta-galactosidase
- betaglucuronidase maltose binding protein
- luciferase green fluorescent protein
- GFP green fluorescent protein
- HcRed HcRed
- DsRed cyan fluorescent protein
- reporter proteins may be conjoined, with or without a peptide linker (such as [GGGSJn (SEQ ID NO: 16), G n , [EAAAK] conjunction (SEQ ID NO: 17), or PAPAP (SEQ ID NO: 18) where n is the number of motif repeats), to any of the aforementioned target nucleic acid sequences, thereby yielding a fusion protein with double function or function attributable to each portion or segment fused together.
- a peptide linker such as [GGGSJn (SEQ ID NO: 16), G n , [EAAAK] come (SEQ ID NO: 17), or PAPAP (SEQ ID NO: 18) where n is the number of motif repeats
- recombinant refers to nucleic acid that is formed by experimentally recombining nucleic acid sequences and sequence elements.
- a recombinant host would be any host receiving a recombinant nucleic acid and the term “recombinant protein” refers to protein produced by such a host.
- expression refers to the process by which a polypeptide is produced from DNA. The process involves the transcription of the gene into mRNA and the translation of this mRNA into a polypeptide. Depending on the context in which it is used, the term “expression” may refer to the production of RNA, protein or both.
- operably linked refers to genetic elements that are joined in such a manner that enables them to carry out their normal functions.
- a gene is operably linked to a promoter when its transcription is under the control of the promotor and such transcription produces the protein normally encoded by the gene.
- vector refers to a nucleic acid sequence capable of transporting another nucleic acid to which it has been linked.
- vectors and plasmids useful for transformation of a variety of host cells are provided.
- Vectors and plasmids are common and commercially available from companies such as Invitrogen Corp. (Carlsbad, CA), Stratagene (La Jolla, CA), New England Biolabs, Inc. (Beverly, MA) and Addgene (Cambridge, MA).
- Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes.
- the term "episomal or expression vector” or comparable terms refer to a vector which is capable of inducing the expression of a nucleic acid sequence encoding a gene that has been cloned into it after transformation into a cell.
- the cloned nucleic acid sequence is usually placed under the control of (i.e., operably linked to) certain regulatory sequences such as a promoter.
- recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
- "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) hereby incorporated by reference in its entirety. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
- vector refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
- Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, doublestranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
- a vector of the invention can be a single-copy or multi-copy vector, including, but not limited to, a BAC (bacterial artificial chromosome), a fosmid, a cosmid, a plasmid, a suicide plasmid, a shuttle vector, a PI vector, an episome, or YAC (yeast artificial chromosome) or any other suitable vector.
- viral vector Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno- associated viruses).
- Viral vectors also include polynucleotides carried by a virus for transfection into a host cell.
- Viral vectors include those where additional DNA segments can be ligated into the viral genome, a bacteriophage or viral genome, or any other suitable vector.
- the host cells can be any cells in which the vector is able to replicate.
- vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid” and “vector” can be used interchangeably. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
- viral vectors e.g., replication defective retroviruse
- the vector or plasmid contains sequences directing transcription and translation of a relevant gene or genes and sequences allowing autonomous replication or chromosomal integration.
- Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcription termination. Both control regions may be derived from genes homologous to the transformed host cell, although it is to be understood that such control regions may also be derived from genes that are not native to the species chosen as a production host.
- phages and their genetic material are provided.
- the terms "phage” and “bacteriophage” are used interchangeably. Phage can be distinguished from each another based on their genetic composition and or their virion morphology.
- Some phage have double stranded DNA genomes, including phage of the Corticoviridae, Opothrixviridae, Plasmaviridae, Myrovridae, Siphoviridae, Sulfolobus, Podoviridae, Tectiviridae and Fuselloviridae families.
- Other phage have single stranded DNA genomes, including phage of the Microviridae and Inoviridae families.
- phage have RNA genomes, including phage of the Leviviridae and Cystoviridae families.
- Exemplary bacteriophage include, but are not limited to, Wphi, Mu, Tl, T2, T3, T4, T5, T6, T7, PI, P2, P4, P22, fd, phi6, phi29, phiC31, phi80, phiX174, SP01, M13, MS2, PM2, SSV-1, L5, PRD1, Qbeta, lambda, UC-1, HK97, HK022 and the like.
- Embodiments of the present disclosure include the use of an inducible system as described herein in a plasmid as well as an entity integrated into the host cell genome, via plasmids with enzymatic elements that direct chromosomal integration of expression cassettes encoded on the plasmid or any kind of suicidal plasmids that leverage the recombination machinery of the cell for integration into its genome.
- Such vectors are described in Ortiz- Martin et al., J Microbiol Methods. 2006 Dec;67(3):395-407. Epub 2006 Jun 5 hereby incorporated by reference in its entirety and can be designed by those of skill in the art based on the present disclosure.
- promoter sequences may be constitutive, inducible or repressible.
- promoter refers to a DNA sequence that initiates the transcription of a gene. Promoters are typically found 5' to the gene and located proximal to the start codon. If a promotor is of the inducible type (i.e., exemplary tetracycline inducible promoters of the present disclosure), then the rate of transcription increases in response to an inducing agent or binding agent, i.e. tetracycline.
- the promoter can be modified to include one or more transcription repressor protein binding sites, also referred to herein as operator sequences, to improve the regulatory functionality of the promoter in response to an inducing agent, such as tetracycline.
- an inducing agent such as tetracycline.
- the driving promoter sequence for any endogenous protein can be used in the methods described herein.
- the driving promoter for any Lactobacillus phage protein can be used in the methods described herein.
- Exemplary host strains include L. delbruckii, L. gasseri, and L. rhamnosus GG) and other host strains as described herein.
- Exemplary promoter sequences include the slpA promoter sequence from L. acidophilus, the clpC promoter L. fermentum BR11, the lack promoter from L. lactis, the Idh promoter from L. plantarum, L. casei, or L. reuteri, the pgm promoter from L. agilis, and the ermB promoter from E. faecalis.
- One of skill in the art will readily be able to identify cognates of these exemplary promoters in sister organisms, and other promoter sequences in addition to the slpA promoter sequence through analysis of sequence databases.
- Such databases include whole genome DNA sequences that can be mined for promoter elements, and transcriptome RNA sequences, that can be sorted by apparent expression strength through computation of the relative abundance via the quantification of transcripts (e.g., 'RPKM').
- Highly expressive promoters can thus be predicted from RNA transcripts exhibiting high transcriptional counts.
- previously published transcriptome data from L. delbrueckii H Zheng et al. Strans-specific RNA-seq analysis of Lactibacillus delbrueckii subsp. Bulgaricus transcriptome. Mol. Biosys , 2016, 12, 508 hereby incorporated by reference in its entirety
- LBU_1429, LBU_0225, LBU_1379, and LBU_1747 whose promoter sequences are exemplary based on the present disclosure.
- computational techniques known to those of skill in the art can be used to identify all predicted promoter sequences from all sequenced Lactobacillus phages. Particularly exemplary are Lactobacillus phages as most phage genes tend to be strongly expressed.
- Synthetically derived promoter sequences can also be used, i.e., computationally optimized sequences generated by identifying consensus sequences from known databases where every permutation of displayed bases can be strung together into a potential promoter and where blank positions can be filled with any of A, T, G, or C.
- Fig. 3 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus delbruckii.
- Fig. 4 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus rhamnosus GG.
- Fig. 5 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus gasseri.
- Fig. 6 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus Phages.
- consensus sequences provide the relative frequencies of an A, T, G, or C occurring at each position of the consensus promoter sequence, which can be used to generate libraries of synthetic promoters that are theoretically optimized for robust expression in that host (in the case a strain-specific consensus as in Fig. 4 and 5) or for Lactobacilli in general (in the case of a phage-derived consensus as in Fig. 6).
- Initiation control regions or promoters which are useful to drive expression of the relevant pathway coding regions in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genetic elements is suitable for the present invention including, but not limited to, lac, ara, tet, trp, IPL, IPS, T7, tac, and trc (useful for expression in Escherichia coli and Pseudomonas); the amy, apr, npr promoters and various phage promoters useful for expression in Bacillus subtilis, and Bacillus licheniformis; nisA, orfK, and xylT promoters (useful for expression in Gram-positive bacteria, Eichenbaum et al.
- regulatory element is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. catabolite repressive elements, transcription termination signals, such as polyadenylation signals and poly-U sequences).
- promoters e.g., promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. catabolite repressive elements, transcription termination signals, such as polyadenylation signals and poly-U sequences).
- IRES internal ribosomal entry sites
- tissue-specific regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).
- a tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes).
- Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
- a vector may comprise one or more pol m promoter (e.g.
- pol m promoters 1, 2, 3, 4, 5, or more pol m promoters
- pol ⁇ promoters e.g. 1, 2, 3, 4, 5, or more pol ⁇ promoters
- pol I promoters e.g. 1, 2, 3, 4, S, or more pol I promoters
- pol m promoters include, but are not limited to, U6 and HI promoters.
- pol ⁇ promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter and Pol ⁇ promoters described herein.
- RSV Rous sarcoma virus
- CMV cytomegalovirus
- PGK phosphoglycerol kinase
- enhancer elements such as WPRE; CMV enhancers; the R- U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981).
- WPRE WPRE
- CMV enhancers the R- U5' segment in LTR of HTLV-I
- SV40 enhancer SV40 enhancer
- the intron sequence between exons 2 and 3 of rabbit ⁇ -globin Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981.
- a vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.
- a terminator sequence includes a section of nucleic acid sequence that marks the end of a gene or operon in genomic DNA during transcription. This sequence mediates transcriptional termination by providing signals in the newly synthesized mRNA that trigger processes which release the mRNA from the transcriptional complex. These processes include the direct interaction of the mRNA secondary structure with the complex and or the indirect activities of recruited termination factors. Release of the transcriptional complex frees RNA polymerase and related transcriptional machinery to begin transcription of new mRNAs. Terminator sequences include those known in the art and identified and described herein. Rho- independent, hairpin-forming terminator sequences are of particular use in lactic acid bacteria, and effective terminators include, but are not limited to, the rrnB Tl terminator sequence:
- Foreign nucleic acids may be introduced into a cell using any method known to those skilled in the art for such introduction.
- Such methods include transfection, transformation, transduction, infection (e.g., viral transduction), injection, microinjection, gene gun, nucleofection, nanoparticle bombardment, transformation, conjugation, by application of the nucleic acid in a gel, oil, or cream, by electroporation, using lipid-based transfection reagents, or by any other suitable transfection method.
- transfection transformation, transduction, infection (e.g., viral transduction), injection, microinjection, gene gun, nucleofection, nanoparticle bombardment, transformation, conjugation, by application of the nucleic acid in a gel, oil, or cream, by electroporation, using lipid-based transfection reagents, or by any other suitable transfection method.
- transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection (e.g., using commercially available reagents such as, for example, LIPOFECTIN® (Invitrogen Corp., San Diego, CA), LIPOFECT AMINE® (Invitrogen), FUGENE® (Roche Applied Science, Basel, Switzerland), JETPEITM (Polyplus-transfection Inc., New York, NY), EFFECTENE® (Qiagen, Valencia, CA), DREAMFECTTM (OZ Biosciences, France) and the like), or electroporation (e.g., in vivo electroporation).
- LIPOFECTIN® Invitrogen Corp., San Diego, CA
- LIPOFECT AMINE® Invitrogen
- FUGENE® Roche Applied Science, Basel
- Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals. Methods and materials of non-viral delivery of nucleic acids to cells further include biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos.
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024.
- the present disclosure provides a TetR-PltetO system using different promoters than are featured in the original TetR-PltetO system, so as to function in lactic acid bacteria.
- the TetR-PltetO system drives the expression of the gene encoding the efflux pump TetA (which provides antibiotic resistance against tetracycline in bacteria).
- TetR is a transcriptional repressor that prevents the transcription of the tetA gene from the PltetO promoter in absence of tetracycline, by means of attaching to the so-called tetO operator boxes (the TetR binding sites).
- TetR disengages from PltetO, allowing access by RNA polymerase and thus permitting the transcription of the resistance gene tetA. This way, the transmembrane efflux pump is produced only when needed.
- Lactobacillus promoters frequently contain AT-rich upstream promoter elements that can interact with a or ⁇ factors and are thus important for robust expression. Therefore, to design a functional tetracycline response promoter for use in Lactobacilli, the promoter sequence that drives the expression of the s-layer protein A (slpA) in L acidophilus is manipulated in a manner to operably link it to tetracycline.
- This promoter exhibits strong, robust expression of heterologous protein in diverse species of Lactobacilli, making it an exemplary design template (A. McCracken et al. Analysis of promoter sequences from Lactobacillus and Lactococcus and their activity in several Lactobacillus species. Arch Microbiol 2000 173:383-389).
- the tetO operator box sequence from the PltetO system was inserted into various regions within the promoter sequence.
- Variant 1 The relative locations of the tetR operators were preserved as they exist in the E. coli PltetO expression system However, a single base pair substitution was made within the tetO box downstream of the -10 sequence, in order to preserve the base encoding for the transcriptional start site (TSS) for slpA, as the tetO placement overlaps with that position (i.e., the C in the 7 th base of the tetO sequences was mutated to a G) as shown in Fig. 7.
- TSS transcriptional start site
- Variant 2 In this variant, the tetO boxes were inserted in locations that minimally perturb the -3S/-10, and upstream promoter sequence region. They are placed subsequent to the transcriptional start site, so that TetR protein binding physically restricts processing by RNA polymerase, rather than preventing RNA polymerase binding in the first place (as is encoded by the tetO placement in Variant 1). See Fig. 8.
- Variant 3 This design mimics the relative placement of operator boxes common to carbohydrate linked induction such as lactose and trehalose. The tetO boxes are placed 5' to the "upstream promoter element" and 5' to the RBS. See Fig. 9.
- Variant 4 This design combines the principles of Variants 2 and 3 together to account for a potential secondary issue.
- Prior literature has demonstrated that slpA owes its expression strength to the high degree of mRNA stability afforded by the 5' untranslated region of the promoter (from the TSS to the RBS), which forms a high-free-energy RNA hairpin to protect mRNA species from 5' mediated degradation. See Narita et al. Appl Microbiol Biotechnol 73:366-373 (2006).
- the hairpin is such that the RBS is in a low energy binding region of the hairpin and is thus still accessible to the ribosome.
- Variants 2 and 3 alter the binding free energy of the mRNA.
- Fig. 11 depicts minimum free energy mRNA structural folding predictions.
- TetR meaning the inserted promoters are not repressed, and should be constitutively active
- E. coli harboring these plasmids were grown to stationary phase (where wild-type slpA promter expression is strongest), and all variants exhibited equivalent expression strength to the original promoter. Subsequently, this test was replicated in L rhamnosus GG. In this setting, only variant 2 exhibited measurable expression (3 fold-less than the wild-type promoter). Therefore, only variant 2 was selected for testing in the presence of TetR.
- the other variants may exhibit function in other strains of Lactobacilli, and would as such be rescreened when switching strains.
- the promoter sequence may be further edited to replace the A in the -13 position upstream of the -10 box with a G.
- 25% of Lactobacilli exhibit a TG dinucleotide motif in the -13/-14 positions of their promoter sequences, so when implementing the slpA promoter, or engineered variants thereof, in these strains, this nucleotide substitution may yield more robust expression. See McCracken et al. J Bacteriol 181(20):6569-6572 (1999).
- the TetR coding region from PltetO was then transferred to a plasmid, fused upstream of, but in reverse complement to the promoter, so as to eliminate the potential for transcriptional read through by DNA polymerase between the two.
- no repression of the promoter was observed in Lactobacillus, due to the same reason the original PltetO promoter exhibited no function - the promoter driving expression of TetR was not sufficiently active.
- the promoter sequence was replaced with constitutive promoters native to Lactobacilli. Selection of the promoter is important to the repressor function. Weak promoters driving low expression of TetR will result in a "leaky", basal expression in the absence of induction agent.
- TetR has high affinity to the tetO sequence, so overexpression of TetR will reduce the dynamic range of induced expression. Accordingly, the promoter for the ribosomal RNA 3-a from L. plantarum was selected, because its expression strength is S-fold weaker than that of slpA. See Fig. 12. An effective choice for the promoter of TetR is not limited to that of rRNA3-a. Published data indicate that the clpC promoter L. fermentum BR11 , the lacA promoter from L. lactis, the Idh promoter from L. plantarum, L. casei, or L. reuteri, the pgm promoter from L.
- the wild-type slpA promoter itself can also be utilized as the promoter for TetR - with the potential benefit of maximally reducing any leakage from the induction system (basal expression in the absence of an inducer), since it is as strong or stronger than any of the engineered slpA variants. However this may require tuning in order to preserve an optimal dynamic range during induction.
- TetR-slpA Slight weakening of the promoter sequence associated with TetR (referred to as TetR-slpA) via RBS site mutation,deletion or mutation of the upstream promoter element (AAATATTACAAATAGTATTTTTCGGTCA (SEQ ID NO: 20), or any subsequence thereof), or mutations introduced into the -35 box, the -10 box, or the sequence space between them, may achieve the desired strength relative to the engineered slpA promoter intended for the target protein (referred to as iZpA-target). TetR expression by slpA may also be tuned by the introduction of catabolic repressive elements such as those sensitive to glucose, to thus scale TetR expression by slpA with cellular growth rate.
- variant 2's design may be applied to TetR-slpA using mutated tetO sequences that bind with lower affinity than the original tetO (e.g. via the introduction of point mutations that break the tetO's sequence palindromes), thus scaling tetR expression with the induction by aTc itself (two candidates with weakly binding tetO mutants include TCTCTAACACTGTTAGGG (SEQ ID NO: 21) and TCTGTATCACTGATACGG (SEQ ID NO: 22), as per Bolinteneauet al. ACS /CED 59:3167- 3176 (2014) hereby incorporated by reference in its entirety).
- Embodiments of the present disclosure are directed to an engineered slpA promoter for repression by tetO having the following characteristics.
- the tetO boxes can be shifted up to 22 base pairs (i.e. two Kuhn lengths) upstream or downstream from their present locations in the variants. That is, the tetO boxes can be placed within plus or minus 22 base pairs from the location identified in each variant.
- variant 2 can be readily replicated with any other promoter - since the tetO boxes are located past slpA's transcriptional start site (and regulate promoter function at the stage just after RNA polymerase binding by preventing it from proceeding into the protein reading frame), the sequence region of variant 2 from the transcriptional start site to the RBS can be fused at its 5' end to any promoter within the region of its respective transcriptional start site (see SEQ ID NO: 4, 7). Accordingly, one aspect of the present disclosure is the insertion of one or more tetO boxes within a target promoter's transcriptional start site.
- Such fusions are shown to either preserve or boost the expression strength of several promoters unrelated to slpA, indicating that the embodiments of the present disclosure are not limited to the promoter slpA and can be replicated for other promoters (see Miyoshi et al., FEMS Microbiol Lett. 239(2):205-212 (2004) hereby incorporated by reference in its entirety).
- the effect of fusing slpA's 5' untranslated region to any given promoter can similarly be applied to the expression of TetR, if it is desirable to increase its expression strength, or tune its dynamic range via the introduction of tetO sequences (or mutants thereof) as described above for TetR-slpA (exemplified with the L.
- TetR may be further modulated by codon engineering. Bacteria have varying tRNA abundances that lead to biased translational efficiencies within sets of degenerate codons. Thus, like codons may be substituted to tune the translational efficiency of TetR. For example, the TetR sequence may be receded with the most frequently used tRNAs in Lactobacilli to optimize translational efficiency in this species (see SEQ ID NO: S). Lastly, the principles of potential tetO (or any other repressor operator box sequence) variant design can be applied to any other promoter sequence and will be apparent to those of skill in the art based on the present disclosure.
- the slpA promoter was edited by inserting tetracycline repressor protein binding sites (tetO) at a variety of locations that were then screened for function.
- tetO tetracycline repressor protein binding sites
- Variant design was dictated by the locations of endogenous repressor binding site locations in Lactobacilli, and their endogenous catabolic repressor motifs.
- Custom bioinformatics were also utilized to generate consensus sequences for Lactobacillus promoters in order to identify functionally important sequence spaces to mitigate disruption of promoter function.
- promoter designs were further guided by secondary structure predictions of predicted mRNA.
- the TetR regulon described herein is driven by a L plantarum promoter paired with slpA-tetO variant 2 (current SEQ IDs 1 and 2), into L rhamnosus GG via electroporation with a high copy plasmid. Sequence verified colonies, as well as colonies harboring a negative control plasmid with no fluorescence reporter, were then picked in triplicate, and used to inoculate liquid cultures that were grown overnight. These overnight cultures were then sub- cultured 1/100 into fresh media, in duplicate - one culture containing 10 ng mL aTc, the other containing no inducing agent.
- the culture with inducing agent was then serially diluted by 50%, S times (yielding cultures with S, 2.S, 1.2S, 0.62S, and 0.312S ng/mL of aTc, in addition to the original 10 ng/mL culture). These cultures were then grown to an optical density of 0.2 (to capture lag phase behavior), 0.6 (log phase), and 1.0 (stationary phase), as measured by an optical cell density meter. At each optical density, the fluorescence of all cultures and replicates were measured in absolute units in a fluorimeter. Relative fluorescence units were then computed as a fold change value over the measured fluorescence of the negative control cell cultures that were known to not express fluorescence protein.
- tetracycline inducible promoters as an orthogonal gene expression system can be further modified and verified in a wider array of strains and cells, and the dynamic range of the promoter can be improved by modulation of basal repression strength.
- methods and expression systems as herein described are provided to control production of proteins by probiotic species such as L. rhamnosus GG or L. gasseri while in vivo, which aTc has previously enabled in the gut pathogen, H. pylori, in mouse models (see A. Debowski et al. Development of a tetracycline-inducible gene expression system for the study of Helicobacter pylori pathogenesis. Appl Environ Microbiol. 2013 Dec;79(23):7351-59 hereby incorporated by reference in its entirety.
- an aTc-inducible promoter variant is provided.
- the aTc-inducible promoter variant exhibits low or undetectable levels of leakage. Lowering or preventing leakage is desirable such as in the case of controlling expression of gene editing proteins such as Cas9, where the repressed state ideally has no measurable gene editing activity.
- replacement of a regulon promoter to address leakage may not be desirable insofar as such a replacement may present incompatibility issues with the host.
- the present disclosure provides methods for creating lower leakage variants of an aTc-inducible promoter.
- a promoter variant is provided wherein the sequence space around the tetO binding sites is altered.
- a promoter variant is provided wherein the sequence space around the tetO binding sites is altered to more closely mimic the general tetO binding site sequence space as found in PltetO (which exhibits low leakage in E. coli).
- an altered promoter sequence where the tetR binding site (or binding landing pad) includes a base pair from PltetO that is one nucleotide upstream to the first tetO binding site (SEQ ID NO: 8), the second tetO binding site (SEQ ID NO:9), or both tetO binding sites (SEQ ID NO: 10).
- the promoter sequence of SEQ ID NO:2 is altered to extend the tetR binding landing pad by including one additional base pair from PltetO that is one nucleotide upstream to the first, second, or both tetO binding sites as represented in SEQ ID NO: 8, SEQ ID NO:9 and SEQ ID NO: 10.
- a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 8.
- a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO:9. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 10.
- an altered promoter sequence where the tetR binding site (or binding landing pad) includes a base pair from PltetO that is one nucleotide downstream to the first tetO binding site (SEQ ID NO: 11), the second tetO binding site (SEQ ID NO: 12), or both tetO binding sites (SEQ ID NO: 13), on its 3' end.
- the promoter sequence of SEQ ID NO:2 is altered to extend the tetR binding landing pad by including one additional base pair from PltetO that is one nucleotide downstream to the first, second, or both tetO binding sites as represented in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13.
- the inclusion of the original nucleotide that is 1 base-pair downstream of the tetO binding site in PltetO, on its 3' end has the same effect on TetR binding (as including the 1 base-pair upstream of the tetO binding site), as the tetO sequence is palindromic, and each of the opposite ends of the sequence exhibit the same mechanism of interaction with TetR, albeit with distinct (but identical) helix-turn-helix motifs within the TetR dimer. Carrying over this nucleotide to the first, second, or both tetO binding site sequence, and substituting the affinity-reducing G/C base-pair in that region of results in the more
- a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 11. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 12. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 13.
- an altered promoter sequence includes the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived.
- the promoter sequence of SEQ ID NO:2 is altered to include the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived.
- the intervening 7bp sequence - currently 7bp of the original slpA 5'UTR sequence at that location - is replaced with the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived (which happens in this case to be the -35 binding site sequence of PltetO).
- a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 14.
- a promoter sequence includes one or more or all of the following: (1) a base pair from PltetO that is one nucleotide upstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites; (2) a base pair from PltetO that is one nucleotide downstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites, on its 3' end; and/or (3) the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived.
- a promoter sequence includes all of the following: (1) a base pair from PltetO that is one nucleotide upstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites; (2) a base pair from PltetO that is one nucleotide downstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites, on its 3' end; and (3) the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived.
- an aspect of the present disclosure provides one or more base or base pair alterations (i.e., additions or deletions) include the following: (1) one additional base pair upstream of the first tetO binding site, (2) one additional base pair downstream of the second tetO binding site, and/or (3) replacement of the intervening, 7bp sequence - currently 7bp of the original slpA 5'UTR sequence at that location - with the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived (which in an exemplary emboidment is the -35 binding site sequence of PltetO).
- the alterations are selected to more closely mimic the general tetO binding site sequence space as found in PltetO (which exhibits low leakage in E. coif)-
- replacement of the intervening, 7bp sequence between the tetO binding sites to its original identity serves to more closely replicate the DNA helicity and melting temperature of PltetO at this location, as these factors influence the binding energy of the TetR-tetO complex.
- aTc-inducible slpA promoter variant is provided in SEQ ID NO: IS which includes the alterations above resulting in a combined, maximally repressive variant.
- a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO:15. All of the described alterations work in concert to achieve an inducible system that has essentially undetectable levels of leakage in all phases of growth.
- aTc- inducible slpA promoter variant of SEQ ID NO: 15 no basal expression was detected in the absence of aTc, whether at stationary phase for 0 hours, 2.5 hours, 7.5 hours, and 17.5 hours, as exemplified in L. rhamnosus GG (see Fig. 16).
- Fig. 16 also shows an order of magnitude (10X) reduction in maximum inducible expression.
- the engineered aTc-inducible slpA promoter has been valuable for enabling heterologous protein secretion in Lactobacillus.
- toxicity can be an issue that prevents successful secretion, especially when driving expression of a secreted protein with a strong promoter - this is because it may overload host cell secretion machinery at the expense of proteins that are naturally secreted by the same pathway that are necessary for survival.
- genetic engineering of expression cassettes for secreted proteins is problematic due to frame-shift mutations that prevent protein expression or secretion. This is because cells that secrete toxic levels of heterologous proteins are outcompeted by cells that generate mutations that prevent it in culture, making it difficult to isolate cells that harbor intact genetic elements encoding the desired secretory activity.
- an inducible expression system prevent expression during bacterial culture and clone isolation.
- expression is controlled and kept off during bacterial culture and clone isolation to avoid or lower or reduce or inhibit secretion-induced toxicity.
- the level of a HisTagged, anti-HTV (gpl20) camelid nanobody (J3-VHH) purified from culture supernatant, when secretion of protein was driven by an inducible system (SEQ ID NO: 2) was compared to a system using an uncontrolled, constitutive slpA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The disclosure provides methods of making a tetracycline inducible expression system in a cell. The methods include providing the cell with a first nucleic acid sequence comprising a first promoter operably linked to a tetracycline repressor gene coding sequence, providing the cell with a second nucleic acid sequence comprising a second promoter operably linked to a coding sequence of a gene of interest wherein the second promoter is modified to include one or more tetracycline repressor protein binding sites, and determining the expression of the gene of interest in the presence or absence of tetracycline. The disclosure further provides nucleic acid sequences, vectors and cells including the tetracycline inducible modified promoter.
Description
METHODS OF REGULATING GENE EXPRESSION IN A CELL
RELATED APPLICATION DATA
This application claims priority to U.S. Provisional Application No. 62/478,219 filed on March 29, 2017, which is hereby incorporated herein by reference in its entirety for all purposes.
STATEMENT OF GOVERNMENT INTERESTS
This invention was made with government support under DE-FG02-02ER63445 awarded by Department of Energy. The government has certain rights in the invention.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 29, 2018, is named 010498_01066_WO_SL.txt and is 15,441 bytes in size.
FIELD
The present invention relates in general to methods of regulating gene expression in a cell.
BACKGROUND
Lactobacilli are important industrial microbes in the dairy industry and are heavily targeted for use in vivo due to their FDA status as a generally regarded as safe (GRAS) probiotic organism. However, few genetic tools exist to control gene expression in Lactobacilli. Inducible expression systems are usually based on "borrowing" native regulation responsive to their cognate sugar activators. While several inducible promoters have been tried in
Lactobacilli, all suffer from high levels of basal leakage because the rich media formulations required for the growth of most species already contain non-trivial levels of the inducing sugar. See T. Duong et al. Construction of vectors for inducible and constitutive gene expression in Lactobacillus. Microb Biotech. 2010 Jul;4(3):3S7-67 and S. Heiss et al. Evaluation of novel inducible promoter/repressor systems for recombinant protein expression. Microb Cell Fact. 2016 Mar; 15(50) each of which are hereby incorporated by reference in its entirety.
Induction systems that have been used are the nisin-controlled gene expression (NICE) system and to a lesser extent the pSIP system, which use nisin and sakacin as inducing agents, respectively (see I. Mierau & M. Kleerebezem 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol. 2005 Jul;68(6):705-17 and E. Sorvig et al. High-level, inducible gene expression in Lactobacilus sakei and Lactobacillus plantarum using versatile expression vectors. Microbiology. 2005 151:2439-49 each of which is hereby incorporated by reference in its entirety. While these systems have been used successfully in a variety of lactic acid bacteria in the past decade, they are unwieldy and inefficient. The NICE system, for example, requires its regulatory proteins to be encoded in the chromosome for proper function due to strict requirements of copy control. Since genome integration is a highly-inefficient process in well-studied Lactobacilli (see J.P. van Pijkeren & R.A. Britton. Precision genome engineering in lactic acid bacteria. Microb Cell Fact. 2014 Aug;13(l):S10 hereby incorporated by reference in its entirety), and unavailable in most other strains, the NICE system cannot be easily used (see S. Pavan et al. Adaptation of the nisin- controlled expression system, in Lactobacillus plantarum: a tool to study in vivo biological effects. Appl Environ Microbiol. 2000 66:4427-32 and Wu CM, Lin CF, Chang YC, Chung RC. Construction and characterization of nisin-controlled. expression vectors for use in Lactobacillus reuteri. Biosci Biotechnol Biochem. 2006 70:757-67 each of which are hereby incorporated by reference in its entirety). Furthermore, both nisin and sakacin are bacteriocins,
and their antibiotic effects may be deleterious to the host species. There is a continuing need for methods and expression systems with improved control for gene expression.
SUMMARY
The present disclosure provides an inducible system for control of nucleic acid expression, such as gene expression, in lactic acid bacteria based on the use of an agent (i.e., binding agent or cognate binding agent) to bind to a transcription repressor protein in a manner to allow a constitutive promoter to begin transcription of a target nucleic acid or to otherwise control an otherwise constitutive promoter's activity insofar as the binding of the transcription repressor protein prevents transcription using the promoter and the binding of the agent to the transcription repressor protein allows transcription by the promoter. According to one aspect, a lactic acid bacterial cell includes a constitutive promoter sequence that has been altered to include one or more transcription repressor protein binding sites. The altered constitutive promoter sequence is operable when the one or more transcription repressor protein binding sites are unbound by a corresponding transcription repressor protein. According to one aspect, insertion of the one or more transcription repressor protein binding sites does not alter or significantly alter the ability of the constitutive promoter sequence to operate or function. Accordingly, transcription by the cell of the target nucleic acid sequence proceeds. When a transcription repressor protein is provided to the cell, such as by expression of a foreign nucleic acid sequence encoding for the corresponding transcription repressor protein, the transcription repressor protein binds to the transcription repressor protein binding site and transcription of the target nucleic acid sequence is repressed. According to one aspect, the transcription repressor protein may be allosteric. When a cognate binding agent is introduced to the cell, the binding agent binds to the transcription repressor protein causing an allosteric change which removes the transcription repressor protein from the transcription repressor protein binding site
or otherwise prevents or inhibits binding of the transcription repressor protein to the transcription repressor protein binding site. As a result, transcription of the target nucleic acid sequence is activated. The nucleic acid sequence within the cell that includes the promoter sequence and the one or more transcription repressor binding sites may be referred to as an agent-responsive element to the extent that the altered promoter sequence (when the transcription repressor protein is bound to the transcription repressor protein binding site) is responsive to the binding agent, i.e., transcription is activated.
According to one exemplary embodiment, lactic acid bacteria are genetically modified to include a tetracycline-responsive element operably linked to a target nucleic acid sequence, such that the tetracycline-responsive element is inducible in the presence of tetracycline to initiate transcription of the target nucleic acid sequence into a corresponding mRNA and translation into a corresponding amino acid sequence. Methods of making lactic acid bacterial cells including an inducible system for control of gene expression based on agent-responsive promoters or elements, such as tetracycline-responsive promoters, genetic constructs and the use of such cells are also disclosed.
According to one aspect, a method is provided for controlling the expression of one or more proteins by a lactic acid bacterial cell within a subject including introducing into the subject a lactic acid bacterial cell or population of lactic acid bacterial cells including (1) an endogenous constitutive promoter sequence modified to include one or more transcriptional repressor protein binding sites, wherein the promoter sequence is operably linked to one or more target nucleic acid sequences encoding the one or more proteins; and (2) exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and
providing the subject with a cognate binding agent which binds to the one or more transcriptional repressor proteins to activate the promoter and induce transcription of the one or more target nucleic acid sequences.
Further features and advantages of certain embodiments of the present invention will become more fully apparent in the following description of embodiments and drawings thereof, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The foregoing and other features and advantages of the present embodiments will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings in which:
Fig. 1 depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. rhamnosus GG.
Fig. 2 depicts data of gene expression of L. delbrueckii 2038.
Fig. 3 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus delbruckii.
Fig. 4 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus rhamnosus GG.
Fig. 5 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus gasseri.
Fig. 6 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus Phages.
Fig. 7 depicts the nucleic acid sequence design for Variant 1 (SEQ ID NO: 24).
Fig. 8 depicts the nucleic acid sequence design for Variant 2 (SEQ ID NO: 25).
Fig. 9 depicts the nucleic acid sequence design for Variant 3 (SEQ ID NO: 26).
Fig. 10 depicts the nucleic acid sequence design for Variant 4 (SEQ ID NO: 27).
Fig. 11 depicts in schematic minimum free energy mRNA structural folding predictions for various mRNA structures.
Fig. 12 depicts fluorescence data of relative expression strengths for the promoter for the ribosomal RNA 3-a from L. plantarum and slpA.
Fig. 13 depicts data demonstrating that slpA with a deletion successfully drives repressor function across a dynamic range of 106 in EL coli, when paired with slpA-tetO variant 2.
Fig. 14 depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. gasseri.
Fig. IS depicts the results of repression and expression of a fluorescent protein in the absence and presence of aTc in L. gasseri, with a hybrid promoter variant.
Fig. 16 depicts data showing suppressed leakage of an aTc-inducible slpA promoter variant modified to more closely resemble the general tetO binding site sequence space of PltetO.
Fig. 17 is a gel image of an experiment showing expression of HisTagged, anti-HTV (gpl20) camelid nanobody (J3-VHH) using an aTc-inducible expression cassette encoding J3- VHH secretion.
DETAILED DESCRIPTION
The practice of certain embodiments or features of certain embodiments may employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology,
recombinant DNA, and so forth which are within ordinary skill in the art. Such techniques are explained fully in the literature. See e.g., Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition (1989), OLIGONUCLEOTIDE SYNTHESIS (M. J. Gait Ed., 1984), ANIMAL CELL CULTURE (R. I. Freshney, Ed., 1987), the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J. M. Miller and M. P. Calos eds. 1987), HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, (D. M. Weir and C. C. Blackwell, Eds.), CURRENT PROTOCOLS EST MOLECULAR BIOLOGY (F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Siedman, J. A. Smith, and K. Struhl, eds., 1987), CURRENT PROTOCOLS EST IMMUNOLOGY (J. E. coligan, A. M Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); ANNUAL REVIEW OF IMMUNOLOGY; as well as monographs in journals such as ADVANCES IN IMMUNOLOGY. All patents, patent applications, and publications mentioned herein, both supra and infra, are hereby incorporated herein by reference.
Terms and symbols of nucleic acid chemistry, biochemistry, genetics, and molecular biology used herein follow those of standard treatises and texts in the field, e.g., Kornberg and Baker, DNA Replication, Second Edition (W.H. Freeman, New York, 1992); Lehninger, Biochemistry, Second Edition (Worth Publishers, New York, 197S); Strachan and Read, Human Molecular Genetics, Second Edition (Wiley-Liss, New York, 1999); Eckstein, editor, Oligonucleotides and Analogs: A Practical Approach (Oxford University Press, New York, 1991); Gait, editor, Oligonucleotide Synthesis: A Practical Approach ( RL Press, Oxford, 1984); and the like.
Additional useful methods are described in manuals including Advanced Bacterial Genetics (Davis, Roth and Botstein, Cold Spring Harbor Laboratory, 1980), Experiments with Gene Fusions (Silhavy, Berman and Enquist, Cold Spring Harbor Laboratory, 1984),
Experiments in Molecular Genetics (Miller, Cold Spring Harbor Laboratory, 1972) Experimental Techniques in Bacterial Genetics (Maloy, in Jones and Bartlett, 1990), and A Short Course in Bacterial Genetics (Miller, Cold Spring Harbor Laboratory 1992) each of which are hereby incorporated by reference in its entirety.
It is to be understood that embodiments of the present disclosure are intended to utilize the particular sequences disclosed herein and sequences having at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to the particular sequence disclosed herein.
The present disclosure provides a lactic acid bacterial cell including a first exogenous nucleic acid sequence comprising an agent-responsive element operably linked to a target nucleic acid sequence, such that the agent-responsive element is inducible in the presence of the agent to initiate transcription of the target nucleic acid sequence into a corresponding mRNA and translation into a corresponding amino acid sequence. According to one aspect, the agent bonds to a transcriptional repressor protein which may or may not be bound to a transcriptional repressor protein binding site to cause an allosteric or conformational change to the transcriptional repressor protein thereby releasing the transcriptional repressor protein from the transcriptional repressor protein binding site or thereby preventing binding of the transcriptional repressor protein to the transcriptional repressor protein binding site, thereby allowing transcription of the target nucleic acid sequence.
According to one aspect, the agent-responsive element includes a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins, wherein the constitutive promoter sequence within the agent-responsive element is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins.
According to one aspect, the agent-responsive element includes a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites and wherein the lactic acid bacterial cell further includes an exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and wherein, the agent activates the promoter, i.e. agent-responsive promoter or element, and induces transcription of the target nucleic acid sequence.
Aspects of the present disclosure include the genetic modification of a cell to include foreign genetic material which can then be expressed by the cell. The cell may be modified to include any other genetic material or elements useful in the expression of a nucleic acid sequence. Foreign genetic elements may be introduced or provided to a cell using methods known to those of skill in the art. A genetically modified cell encompasses lactic acid bacterial cells that have been engineered to include an episomal or expression vector or otherwise incorporate a nucleic acid sequence, such as for example in the genome or the cell. Cells and techniques for cellular transformation are well known in the art (see e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor (1989)).
Embodiments of the present disclosure provide a genetically modified lactic acid bacterial cell including a first nucleic acid sequence comprising a first promoter operably linked to a DNA binding molecule such as a tetracycline repressor gene coding sequence, and a second nucleic acid sequence comprising a second promoter operably linked to a target nucleic acid sequence such as a coding sequence of a gene of interest wherein the second promoter is modified to include one or more DNA binding molecule binding sites, such as tetracycline repressor protein binding sites.
Embodiments of the present disclosure are directed to methods of making a tetracycline inducible expression system in a lactic acid bacterial cell. The cell is genetically modified to include a first nucleic acid sequence comprising a first promoter operably linked to a tetracycline repressor gene coding sequence, and a second nucleic acid sequence comprising a second promoter operably linked to a coding sequence of a gene of interest wherein the second promoter is modified to include one or more tetracycline repressor protein binding sites. The first promoter drives constitutive expression of a tetracycline repressor. The second promoter regulates the expression of a gene of interest in response to tetracycline induction.
Embodiments of the present disclosure provide for a first nucleic acid sequence including a first promoter operably linked to a tetracycline repressor gene coding sequence. The first promoter can be any promoter that is operable in a lactic acid bacterial cell. Preferably, the first promoter can drive constitutive expression of the tet repressor. In an exemplary embodiment, the first nucleic acid sequence is represented by a sequence having at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 1 and the first promoter is an L. plantarum ribosomal RNA promoter.
Embodiments of the present disclosure provide for a second nucleic acid sequence including a second promoter operably linked to a coding sequence of a gene of interest wherein the promoter is modified to include one or more tetracycline repressor protein binding sites. The second promoter is inducible by an inducing agent. In an exemplary embodiment, the promoter is inducible by tetracycline or its analogs or functional equivalents. The second promoter is operable in lactic acid bacterial cells. In an exemplary embodiment, the second promoter is an slpA promoter. The second promoter is modified to include one or more tetracycline repressor protein binding sites so that tight control of gene expression in the respective prokaryotic or eukaryotic cell can be achieved. In one embodiment, the modified
promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 2 or SEQ ID NO: 4.
Embodiments of the present disclosure provide an expression vector including a nucleic acid sequence including a promoter operably linked to a coding sequence of a gene of interest wherein the promoter is modified to include one or more tetracycline repressor protein binding sites. Further, a polynucleotide sequence can be operably linked to the promoter. The polynucleotide sequence may be a polynucleotide sequence encoding a gene, an antisense polynucleotide, a ribozyme, a fusion protein, a polynucleotide encoding an antibody, or therapeutic protein etc.
Lactic Acid Bacterial Cells
Cells according to the present disclosure include lactic acid bacterial cells. Exemplary lactic acid bacterial cells include bacterial cells within the order LactobacilMes. According to one aspect, bacterial cells include bacterial cells from the genus Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Carnobacterium, Enterococcus, Oenococcus, Tetragenococcus, Vagococcus, or Weisella. According to one aspect, bacterial cells include bacterial cells from the species Lactobacillus acetotolerans, Lactobacillus acidifarinae, Lactobacillus acidipiscis, Lactobacillus acidophilus, Lactobacillus agilis,Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus alvei, Lactobacillus alvi, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylotrophicus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus animata, Lactobacillus antri, Lactobacillus apinorum, Lactobacillus apis, Lactobacillus apodemi, Lactobacillus aquaticus, Lactobacillus aviarius, Lactobacillus backii, Lactobacillus bifermentans, Lactobacillus bombi, Lactobacillus bombicola, Lactobacillus brantae, Lactobacillus brevis, Lactobacillus brevisimilis,
Lactobacillus buchneri, Lactobacillus cacaonum, Lactobacillus camelliae, Lactobacillus capillatus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus catenefornis, Lactobacillus ceti, Lactobacillus coleohominis, Lactobacillus colini, Lactobacillus collinoides, Lactobacillus composti, Lactobacillus concavus, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curieae, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus dextrinicus, Lactobacillus diolivorans, Lactobacillus equi, Lactobacillus equicursoris, Lactobacillus equigenerosi, Lactobacillus fabifermentans, Lactobacillus faecis, Lactobacillus faeni, Lactobacillus faiciminis, Lactobacillus fairaginis, Lactobacillus fermentum, Lactobacillus floricola, Lactobacillus florum, Lactobacillus formosensis, Lactobacillus fornicalis, Lactobacillus fructivorans, Lactobacillus frumenti, Lactobacillus fuchuensis, Lactobacillus furfuricola, Lactobacillus futsaii, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus gastricus, Lactobacillus ghanensis, Lactobacillus gigeriorum, Lactobacillus ginsenosidimutans, Lactobacillus gorillae, Lactobacillus graminis, Lactobacillus guizhouensis, Lactobacillus halophilus, Lactobacillus hammesii, Lactobacillus hamsteri, Lactobacillus harbinensis, Lactobacillus hayakitensis, Lactobacillus heilongjiangensis, Lactobacillus helsingborgensis, Lactobacillus helveticus, Lactobacillus herbarum, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus hokkaidonensis, Lactobacillus hominis, Lactobacillus homohiochii, Lactobacillus hoidei, Lactobacillus iatae, Lactobacillus iners, Lactobacillus ingluviei, Lactobacillus insectis, Lactobacillus insicii, Lactobacillus intermedius, Lactobacillus intestinalis, Lactobacillus iwatensis, Lactobacillus ixorae, Lactobacillus japonicus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus kimbladii, Lactobacillus kimchicus, Lactobacillus kimchiensis, Lactobacillus kisonensis, Lactobacillus kitasatonis, Lactobacillus koreensis, Lactobacillus kullabergensis, Lactobacillus kunkeei, Lactobacillus larvae,
Lactobacillus leichmannii, Lactobacillus letivazi, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mellifer, Lactobacillus mellis, Lactobacillus melliventris, Lactobacillus micheneri, Lactobacillus mindensis, Lactobacillus mixtipabuli, Lactobacillus mobilis, Lactobacillus modestisalitoleians, Lactobacillus mucosae, Lactobacillus mudanjiangensis, Lactobacillus murinus, Lactobacillus nagelii, Lactobacillus namurensis, Lactobacillus nantensis, Lactobacillus nasuensis, Lactobacillus nenjiangensis, Lactobacillus nodensis, Lactobacillus odoratitofui, Lactobacillus oeni, Lactobacillus oligofermentans, Lactobacillus ori, Lactobacillus oryzae, Lactobacillus otakiensis, Lactobacillus ozensis, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus parabuchneri, Lactobacillus paracollinoides, Lactobacillus parafairaginis, Lactobacillus parakefiri, Lactobacillus paralimentarius, Lactobacillus paraplantarum, Lactobacillus pasteurii, Lactobacillus paucivorans, Lactobacillus pentosus, Lactobacillus perolens, Lactobacillus plajomi, Lactobacillus plantarum, Lactobacillus pobuzihii, Lactobacillus pontis, Lactobacillus poicinae, Lactobacillus psittaci, Lactobacillus rapi, Lactobacillus lennanquilfy, Lactobacillus rennini, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rodentium, Lactobacillus Fogosae, Lactobacillus rossiae, Lactobacillus ruminis, Lactobacillus saerimneri, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis, Lactobacillus saniviri, Lactobacillus satsumensis, Lactobacillus secaliphilus, Lactobacillus selangoiensis, Lactobacillus senioris, Lactobacillus senmaizukei, Lactobacillus sharpeae, Lactobacillus shenzhenensis, Lactobacillus sicerae, Lactobacillus silagei, Lactobacillus siliginis, Lactobacillus similis, Lactobacillus songhuajiangensis, Lactobacillus spicheri, Lactobacillus sucicola, Lactobacillus suebicus, Lactobacillus sunkii, Lactobacillus taiwanensis, Lactobacillus thailandensis, Lactobacillus tucceti, Lactobacillus ultunensis, Lactobacillus uvarum, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus vermiforme,
Lactobacillus vespulae, Lactobacillus vini, Lactobacillus wasatchensis, Lactobacillus xiangfangensis, Lactobacillus yonginensis, or Lactobacillus zymae.
Cells according to the present disclosure include any lactic acid bacterial cell such as those listed at world wide website ncbi.nlm.nih.gov/Taxonomy Browser/wwwtax.cgi?id=1578 into which nucleic acids having modified or altered promoter sequences operably linked to a target nucleic acid sequence of interest, such as a gene, can be introduced and expression of the gene of interest can be regulated by an inducing agent as described herein. It is to be understood that the basic concepts of the present disclosure described herein are not limited by cell type.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The recombinant expression vector may include the agent-responsive promoter or element as described herein. The recombinant expression vector may include the nucleic acid encoding the transcriptional repression protein. The recombinant expression vector may include the altered or modified promoter sequence that includes one or more transcriptional repression protein binding sites. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
Agent-Responsive Element
According to one aspect, the disclosure provides an agent-responsive element. The agent responsive element includes one or more of a constitutive promoter sequence, which may be endogenous or exogenous, and one or more exogenous transcriptional repressor protein
binding sites corresponding to one or more transcriptional repressor proteins. The constitutive promoter sequences may be modified or altered to include the one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins. The constitutive promoter sequence combined with one or more exogenous transcriptional repressor protein binding sites is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins. According to one aspect, the presence of the one or more exogenous transcriptional repressor protein binding sites may not inhibit the transcription of a target nucleic acid sequence as activated by the constitutive promoter sequence. The one or more exogenous transcriptional repressor protein binding sites may be placed upstream of the constitutive promoter sequence or within the constitutive promoter sequence. The agent, as described herein, is an entity that binds to the transcriptional repressor protein in a manner to inhibit binding of the transcriptional repressor protein to the transcriptional repressor protein binding site. When binding of the transcriptional repressor protein to the transcriptional repressor protein binding site is inhibited, transcription of the target nucleic acid sequence is promoted or activated through the constitutive promoter.
According to one aspect, a constitutive promoter sequence is modified to include one or more transcriptional repressor protein binding sites. The promoter sequence may be referred to as an altered promoter sequence or a modified promoter sequence. The transcriptional repressor protein binding site has a corresponding transcriptional repressor protein that binds to the transcriptional repressor protein binding site. The transcriptional repressor protein has a cognate binding partner that when bound to the transcriptional repressor protein inhibits binding of the transcriptional repressor protein to the transcriptional repressor protein binding site by way of allosteric change of the transcriptional repressor protein or steric hindrance or other mechanism of inhibition. An exemplary agent-induction system is the tetracycline
induction system which has been used extensively in bacterial, fungal, plant, and mammalian systems. See J.L. Ramos et al. The TetR family of transcriptional repressors. Microbiol Mol Biol Rev. 2005 Jun;69(2):326-56; E. Gari et al. A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae. Yeast. 1997 Jul;13(9):837-48; P. Weinmann et al. A chimeric transactivator allowes tetracycline-responsive gene expression in whole plants. Plant J. 1994 Apr;5(4):559-69 and M. Gossen & II. BujarcL Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. PNAS. 1992 Jun 15;89(12):5547-51 each of which are hereby incorporated by reference in its entirety. According to certain aspects, a tetracycline-regulatable promoter system, with tetracycline being the agent that induces transcription, is exemplary because of its ability to facilitate tight regulation and exhibit superior dynamic range of up to 5000-fold (see R. Lutz & H. Bujard. Independent and tight regulation of transcriptional units in Escheria coli via the LacR O, the TetR/0 and AraC/Il-I2 regulatory elements hereby incorporated by reference in its entirety), as well as its orthogonality to host factors. According to one aspect, the agent- responsive element and the agent are exemplary in their ability to exhibit, in most hosts of interest, little to no crosstalk between the system and host genetics or metabolism. Heterologous gene expression may thus be more reliably controlled by the experimenter. A tetracycline-regulatable promoter system is particularly exemplary. This feature of a tetracycline-regulatable promoter system also enables tetracycline or anhydrous tetracycline (aTc) induction's use in vivo. See X. Xia et al. In vitro- and in v/vo-induced transgene expression in human embryonic stem cells and derivatives. Stem Cells. 2008 Dec;26(2):525- 33 and L.E. Dow et al. Inducible in vivo genome editing with CR1SPR-Cas9. Nat Biotech. Feb 18;33:390-4 each of which are hereby incorporated by reference in its entirety. Cas proteins are found in Streptococcus pyogenes, S. thermophUes, S. aureus or any other strain known to those of skill in the art.
According to one aspect, the promoter is endogenous and is a strong constitutive promoter with a longer promoter sequence into which operator boxes may be placed to control and regulate the promoter. Longer promoter sequences allow operator boxes to be inserted and not abrogate promoter ability but also to stop promoter ability when the transcriptional repressor protein binds.
As used herein, the term "repressor" or "transcriptional repressor protein" refers to a molecule capable of inhibiting the expression of a particular nucleic acid sequence, such as a gene, from a promoter. In effect, the molecule "represses" the expression of the gene from its promoter. In general, repressor systems will readily be recognized by those of skill in the art based on the present disclosure and which include a DNA binding site also referred to as a transcriptional repressor protein binding site or operator sequence and its corresponding binding partner also referred to as a transcriptional repressor protein. When the DNA binding site is included into a DNA sequence in a cell and the corresponding binding partner is provided to the cell, the corresponding binding partner binds to the DNA binding site. Such a system can be used to inhibit transcription when operably linked to a promoter sequence. Such a system can be included into a constitutive promoter sequence to transform the constitutive promoter sequence into an inducible promoter sequence. According to this aspect, the binding of the corresponding binding partner to the DNA binding site within a promoter sequence inhibits transcription of a target nucleic acid sequence operatively connected or linked to the promoter sequence. When the corresponding binding partner is removed from the DNA binding site, the constitutive promoter sequence begins transcription of the target nucleic acid sequence.
According to one aspect, an agent is provided that binds to the transcriptional repressor protein causing a conformational change in the transcriptional repressor protein thereby rendering it unable to bind to the transcriptional repressor protein binding site. In this manner,
the transcriptional repressor protein is allosteric insofar as it can change structure or form when bound by an agent. In this manner, repressor dimerization and function may be disrupted. An agent may also inhibit binding of the transcriptional repressor protein through steric hindrance or other methods.
Transcriptional repressor proteins and their cognate binding sites are known to those of skill in the art and such as the TetR/tetO system, LacR/lacO or TreR/treO (lactose and trehalose controlled repression). For example, the tet repressor (TetR) is a protein that represses gene transcription of the tet operon upon binding to its cognate tet operator sequences tetO (tet binding sites) within the operon promoter. One of skill will readily identify useful TetR sequences based on the present disclosure including those identified in Ramos et al., The TetR Family of Transcriptional Repressors, Microbiology and Molecular Biology Reviews, June 2005, P. 326-356 hereby incorporated by reference in its entirety.
The TetR/tetO system is said to be a tetracycline responsive system insofar as tetracycline, anhydrous tetracycline or suitable derivatives of tetracycline may prevent binding of the tetracycline repressor to the tet operator sequences. Additional agent-responsive promoter systems include metabolite responsive systems such as metabolite-controlled operator boxes paired with their corresponding repressor such as LacR/lacO & TreR/treO (lactose and trehalose controlled repression). Additional repressor systems exist which are based on binding agents such as glucose, mannose, fructose, galactose, sucrose, raffinose, maltose, arabinose, ribose, sorbose, rhamnose, xylose which inhibit binding of a cognate transcriptional repressor protein thereby activating traqnscription. Such repressor systems may be included within any promoter sequence, such as slpA.
According to certain aspects, a cell is genetically modified to include one or more exogenous nucleic acids encoding for a transcriptional repressor protein and wherein the cell includes the cognate transcriptional repressor protein binding site. A binding agent cognate to
the transcriptional repressor protein is also provided. The cell may also be genetically modified to include one or more exogenous nucleic acid sequences including one or more transcriptional repressor protein binding sites. Transcriptional repressor proteins and their corresponding or cognate binding agents are known to those of skill in the art and include those listed in Table 1 below.
Table 1
It is to be understood that the examples of transcriptional repressors and their corresponding binding agents are exemplary only and that one of skill in the art can readily identify additional transcriptional repressors and their corresponding binding agents for use in the present disclosure. Aside from the TetR family of transcriptional repressors, any member of the main bacterial transcriptional repressor families could be similarly implemented. This
list includes members of the ArgR, AsnC/LrP, DeoR, GalR LacI, GntR, IclR, LysR, MerR, MetJ, ModE, PadR and XRE families, not excluding other groups or subgroups of transcriptional regulators from bacterial, phagic or mammalian origin directly used or repurposed for their application in Lactobacilli.
Transcriptional repressors and/or binding agents may be natural or synthetic. One of skill can also design synthetic transcriptional repressors to bind to natural or non-natural cognate nucleic acid sequences and which may further bind natural or non-natural binding agents using methods known to those of skill in the art. The transformed cell is intended to express the transcriptional repressor under suitable conditions. Methods described herein can be used to insert the nucleic acids into the genome of the cells that are responsible for production of transcriptional repressors.
According to one aspect, the transformed, recombinant cell expresses the transcriptional repressor protein which regulates production of a target nucleic acid, for example, by binding to transcriptional repressor protein binding site within a promoter thereby inhibiting transcription of the target nucleic acid. According to one aspect, when expressed, the transcriptional repressor protein prevents the cell from expressing the target nucleic acid, either by blocking the expression (i.e. a repressor) of the target nucleic acid unless the transcriptional repressor protein is bound by the binding agent, which leads to target nucleic acid expression. According to one aspect for an allosteric transcription factor that is a repressor, the repressor protein blocks transcription of the reporter gene by binding as an oligomer to a region of DNA 5' to the reporter gene unless the desired binding agent binds the repressor thereby disrupting the oligomeric behavior and thus frequently preventing the effective binding of the complex to its cognate operator sequences. According to a further aspect, the transformed, recombinant cell is provided with a binding agent which binds to the transcription repressor protein in a manner to promote production of the peptide, polypeptide or amino acid
sequence corresponding to the target nucleic acid sequence. According to one aspect, in the absence of the binding agent, the transcription repressor protein prevents transcription of the target nucleic acid.
Target Nucleic Acid Sequence
Target nucleic acid sequences maybe of any sequences desired to be transcribed. Target nucleic acid sequences include those that encode for therapeutic proteins, diagnostic proteins, reporter proteins, genes or enzymes.
As used herein, "gene" refers to the nucleic acid sequence that undergoes transcription as the result of promoter activity. A gene may code for a particular protein or, alternatively, code for an RNA sequence that is of interest in itself, e.g. because it acts as an antisense inhibitor.
Therapeutic proteins envisioned herein include proteins, such as endogenous proteins, associated with probiotic function (e.g. LGG p40, spaC), antibodies (including IgG, IgE, IgA, scFv and camlid antibodies - that target infectious agents, or host cell-surface proteins and antibody Fc), antimicrobial peptides of mammalian, viral, and bacterial origin (e.g. collistin, caerin, dermaseptin, LL-37, HBD-2) antiviral peptides (e.g. HCV-CSA, Fuzeon), cytokines (e.g. IL-10), allergens (e.g. pollen, nut proteins), worm protein (e.g. hookworm protein), trefoil factor, dietary enzymes, mucin binding proteins (e.g. intJ, GroEL), invasins, antitoxins or any antigen derived from an infectious agent delivered as a vaccination target.
Diagnostic proteins envisioned herein include antibodies that also can be used as diagnostic sensors, reactive oxygen species sensors or temperature sensors.
According to one aspect, the target nucleic acid sequence or downstream gene is a detectable moiety or reporter, such as a fluorescent moiety, such as GFP, that can be detected by fluorimetry, for example. An exemplary detectable moiety is a reporter protein. Reporter
proteins envisioned herein include fluorescent proteins, luminescent proteins, enzymatic reporters such as GusA or PepN. Aspects of the methods described herein may make use of epitope tags and reporter gene sequences as detectable moieties. Non-limiting examples of epitope tags include histidine (His) tags, VS tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, betaglucuronidase, maltose binding protein, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). Exemplary fluorescent protein reporters are provided at world wide website tsienlab.ucsd.edu Samples/Constructs.htm. Any aforementioned instance of reporter proteins may be conjoined, with or without a peptide linker (such as [GGGSJn (SEQ ID NO: 16), Gn, [EAAAK]„ (SEQ ID NO: 17), or PAPAP (SEQ ID NO: 18) where n is the number of motif repeats), to any of the aforementioned target nucleic acid sequences, thereby yielding a fusion protein with double function or function attributable to each portion or segment fused together.
Definitions
As used herein, the term "recombinant" refers to nucleic acid that is formed by experimentally recombining nucleic acid sequences and sequence elements. A recombinant host would be any host receiving a recombinant nucleic acid and the term "recombinant protein" refers to protein produced by such a host.
As used herein, the term "expression" refers to the process by which a polypeptide is produced from DNA. The process involves the transcription of the gene into mRNA and the
translation of this mRNA into a polypeptide. Depending on the context in which it is used, the term "expression" may refer to the production of RNA, protein or both.
As used herein, the term "operably linked" refers to genetic elements that are joined in such a manner that enables them to carry out their normal functions. For example, a gene is operably linked to a promoter when its transcription is under the control of the promotor and such transcription produces the protein normally encoded by the gene.
Vectors
As used herein, the term "vector" refers to a nucleic acid sequence capable of transporting another nucleic acid to which it has been linked. In certain aspects of the invention, vectors and plasmids useful for transformation of a variety of host cells are provided. Vectors and plasmids are common and commercially available from companies such as Invitrogen Corp. (Carlsbad, CA), Stratagene (La Jolla, CA), New England Biolabs, Inc. (Beverly, MA) and Addgene (Cambridge, MA). Vectors used to deliver the nucleic acids to cells as described herein include vectors known to those of skill in the art and used for such purposes.
As used herein, the term "episomal or expression vector" or comparable terms refer to a vector which is capable of inducing the expression of a nucleic acid sequence encoding a gene that has been cloned into it after transformation into a cell. The cloned nucleic acid sequence is usually placed under the control of (i.e., operably linked to) certain regulatory sequences such as a promoter.
In certain exemplary embodiments, recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is
operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) hereby incorporated by reference in its entirety. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, doublestranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. By way of example, but not of limitation, a vector of the invention can be a single-copy or multi-copy vector, including, but not limited to, a BAC (bacterial artificial chromosome), a fosmid, a cosmid, a plasmid, a suicide plasmid, a shuttle vector, a PI vector, an episome, or YAC (yeast artificial chromosome) or any other suitable vector.
Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, lentiviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno- associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Viral vectors include those where additional DNA segments can
be ligated into the viral genome, a bacteriophage or viral genome, or any other suitable vector. The host cells can be any cells in which the vector is able to replicate.
Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
Typically, the vector or plasmid contains sequences directing transcription and translation of a relevant gene or genes and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcription termination. Both control regions may be derived from genes homologous to the transformed host cell, although it is to be understood that such control regions may also be derived from genes that are not native to the species chosen as a production host.
According to certain aspect of the invention, phages and their genetic material are provided. As used herein, the terms "phage" and "bacteriophage" are used interchangeably. Phage can be distinguished from each another based on their genetic composition and or their virion morphology. Some phage have double stranded DNA genomes, including phage of the Corticoviridae, Opothrixviridae, Plasmaviridae, Myrovridae, Siphoviridae, Sulfolobus,
Podoviridae, Tectiviridae and Fuselloviridae families. Other phage have single stranded DNA genomes, including phage of the Microviridae and Inoviridae families. Other phage have RNA genomes, including phage of the Leviviridae and Cystoviridae families. Exemplary bacteriophage include, but are not limited to, Wphi, Mu, Tl, T2, T3, T4, T5, T6, T7, PI, P2, P4, P22, fd, phi6, phi29, phiC31, phi80, phiX174, SP01, M13, MS2, PM2, SSV-1, L5, PRD1, Qbeta, lambda, UC-1, HK97, HK022 and the like. Exemplary phages include lactobacillus phages such as those described in world wide website ncbi.nlin.nm.gov/taxonomy/?term=lactobacillus+phage, including Bacteriophage phiADH, which has been used to transform L. gasseri as described in Appl Environ Microbiol. 2010 Jun; 76(12): 3878-3885 hereby incorporated by reference in its entirety.
Embodiments of the present disclosure include the use of an inducible system as described herein in a plasmid as well as an entity integrated into the host cell genome, via plasmids with enzymatic elements that direct chromosomal integration of expression cassettes encoded on the plasmid or any kind of suicidal plasmids that leverage the recombination machinery of the cell for integration into its genome. Such vectors are described in Ortiz- Martin et al., J Microbiol Methods. 2006 Dec;67(3):395-407. Epub 2006 Jun 5 hereby incorporated by reference in its entirety and can be designed by those of skill in the art based on the present disclosure.
Promoter Sequences
According to methods and constructs described herein, promoter sequences may be constitutive, inducible or repressible. As used herein, the term "promoter" refers to a DNA sequence that initiates the transcription of a gene. Promoters are typically found 5' to the gene and located proximal to the start codon. If a promotor is of the inducible type (i.e., exemplary tetracycline inducible promoters of the present disclosure), then the rate of transcription
increases in response to an inducing agent or binding agent, i.e. tetracycline. The promoter can be modified to include one or more transcription repressor protein binding sites, also referred to herein as operator sequences, to improve the regulatory functionality of the promoter in response to an inducing agent, such as tetracycline. It is to be understood that the driving promoter sequence for any endogenous protein can be used in the methods described herein. The driving promoter for any Lactobacillus phage protein can be used in the methods described herein. One of skill will have ready access to the identification of such promoter sequences of any host organism of interest. Exemplary host strains include L. delbruckii, L. gasseri, and L. rhamnosus GG) and other host strains as described herein. Exemplary promoter sequences include the slpA promoter sequence from L. acidophilus, the clpC promoter L. fermentum BR11, the lack promoter from L. lactis, the Idh promoter from L. plantarum, L. casei, or L. reuteri, the pgm promoter from L. agilis, and the ermB promoter from E. faecalis. One of skill in the art will readily be able to identify cognates of these exemplary promoters in sister organisms, and other promoter sequences in addition to the slpA promoter sequence through analysis of sequence databases. Such databases include whole genome DNA sequences that can be mined for promoter elements, and transcriptome RNA sequences, that can be sorted by apparent expression strength through computation of the relative abundance via the quantification of transcripts (e.g., 'RPKM'). Highly expressive promoters can thus be predicted from RNA transcripts exhibiting high transcriptional counts. For example, previously published transcriptome data from L. delbrueckii (H Zheng et al. Strans-specific RNA-seq analysis of Lactibacillus delbrueckii subsp. Bulgaricus transcriptome. Mol. Biosys , 2016, 12, 508 hereby incorporated by reference in its entirety) can be analyzed by plotting the RPKM profile of this strain. See Fig. 2. This procedure highlights the highly expressed genes, LBU_1429, LBU_0225, LBU_1379, and LBU_1747, whose promoter sequences are exemplary based on the present disclosure.
According to one aspect, computational techniques known to those of skill in the art can be used to identify all predicted promoter sequences from all sequenced Lactobacillus phages. Particularly exemplary are Lactobacillus phages as most phage genes tend to be strongly expressed. Synthetically derived promoter sequences can also be used, i.e., computationally optimized sequences generated by identifying consensus sequences from known databases where every permutation of displayed bases can be strung together into a potential promoter and where blank positions can be filled with any of A, T, G, or C. Sequences with at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity with any of these resulting, synthetic promoter sequences have similar efficacy. Fig. 3 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus delbruckii. Fig. 4 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus rhamnosus GG. Fig. 5 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus gasseri. Fig. 6 is a graph depicting a consensus sequence generated from all sequenced Lactobacillus Phages. These consensus sequences provide the relative frequencies of an A, T, G, or C occurring at each position of the consensus promoter sequence, which can be used to generate libraries of synthetic promoters that are theoretically optimized for robust expression in that host (in the case a strain-specific consensus as in Fig. 4 and 5) or for Lactobacilli in general (in the case of a phage-derived consensus as in Fig. 6).
Initiation control regions or promoters, which are useful to drive expression of the relevant pathway coding regions in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genetic elements is suitable for the present invention including, but not limited to, lac, ara, tet, trp, IPL, IPS, T7, tac, and trc (useful for expression in Escherichia coli and Pseudomonas); the amy, apr, npr promoters
and various phage promoters useful for expression in Bacillus subtilis, and Bacillus licheniformis; nisA, orfK, and xylT promoters (useful for expression in Gram-positive bacteria, Eichenbaum et al. AppL Environ. Microbiol 64(8):2763-2769 (1998)); Sorvig et al. FEMS Microbiol Lett. 229:119-126 (2003), Miyoshi et al., FEMS Microbiol Lett. 239(2):205-212 (2004)); the lac, tre, FOS promoters (useful for expression in Lactobacilli, Duong et al. Microb. Biotech, 4(3):357-367 (2010)); ribosomal RNA subunit promoters and synthetic derivatives thereof such as the synthetic Pll promoter (useful for expression in Lactobacillus plantarum, Rud et al., Microbiology 152:1011-1019 (2006)). Termination control regions may also be derived from various genes native to the preferred hosts.
Regulatory elements are contemplated for use with the methods and constructs described herein. The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. catabolite repressive elements, transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS EST ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector may comprise one or more pol m promoter (e.g. 1, 2, 3, 4, 5, or more pol m promoters), one or more pol Π promoters (e.g. 1, 2, 3, 4, 5, or more pol Π promoters), one or more pol I promoters
(e.g. 1, 2, 3, 4, S, or more pol I promoters), or combinations thereof. Examples of pol m promoters include, but are not limited to, U6 and HI promoters. Examples of pol Π promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter and Pol Π promoters described herein. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R- U5' segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.
Terminators
Aspects of the methods described herein may make use of terminator sequences. A terminator sequence includes a section of nucleic acid sequence that marks the end of a gene or operon in genomic DNA during transcription. This sequence mediates transcriptional termination by providing signals in the newly synthesized mRNA that trigger processes which release the mRNA from the transcriptional complex. These processes include the direct interaction of the mRNA secondary structure with the complex and or the indirect activities of recruited termination factors. Release of the transcriptional complex frees RNA polymerase and related transcriptional machinery to begin transcription of new mRNAs. Terminator
sequences include those known in the art and identified and described herein. Rho- independent, hairpin-forming terminator sequences are of particular use in lactic acid bacteria, and effective terminators include, but are not limited to, the rrnB Tl terminator sequence:
Genetic Modification
Foreign nucleic acids (i.e., those which are not part of a cell's natural nucleic acid composition) may be introduced into a cell using any method known to those skilled in the art for such introduction. Such methods include transfection, transformation, transduction, infection (e.g., viral transduction), injection, microinjection, gene gun, nucleofection, nanoparticle bombardment, transformation, conjugation, by application of the nucleic acid in a gel, oil, or cream, by electroporation, using lipid-based transfection reagents, or by any other suitable transfection method. One of skill in the art will readily understand and adapt such methods using readily identifiable literature sources.
As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection (e.g., using commercially available reagents such as, for example, LIPOFECTIN® (Invitrogen Corp., San Diego, CA), LIPOFECT AMINE® (Invitrogen), FUGENE® (Roche Applied Science, Basel, Switzerland), JETPEI™ (Polyplus-transfection Inc., New York, NY), EFFECTENE® (Qiagen, Valencia, CA), DREAMFECT™ (OZ Biosciences, France) and the like), or electroporation (e.g., in vivo electroporation). Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.
Methods and materials of non-viral delivery of nucleic acids to cells further include biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024.
The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.
EXAMPLE I
Methods of making a tetracycline inducible expression system in Lactobacilli
The present disclosure provides a TetR-PltetO system using different promoters than are featured in the original TetR-PltetO system, so as to function in lactic acid bacteria. In general, the TetR-PltetO system drives the expression of the gene encoding the efflux pump TetA (which provides antibiotic resistance against tetracycline in bacteria). TetR is a transcriptional repressor that prevents the transcription of the tetA gene from the PltetO promoter in absence of tetracycline, by means of attaching to the so-called tetO operator boxes (the TetR binding sites). In the presence of the antibiotic, TetR disengages from PltetO, allowing access by RNA polymerase and thus permitting the transcription of the resistance gene tetA. This way, the transmembrane efflux pump is produced only when needed.
An expression system that is inducible by tetracycline in Lactobacilli is described as follows. It was first verified that Lactobacilli possess no resistance genes that would adulterate
any induction system based on the addition of tetracycline or any of its analogs. A BLAST analysis of the TetR protein sequence as well as the TetA tetracycline efflux pump that drives resistance was performed, across all available Lactobacillus proteomes and potential homologs in L lactis, and L plantarum were identified, because they carry a transferrable plasmid harboring tetM and tetS genes. These plasmids can be eliminated from these strains with novobiocin so that this system can still be implemented in them, but regardless, no other strain of Lactobacillus possessed any sequences pertinent to tetracycline. This was imperically validated by testing several strains (L. rhamnosus GG, L gasseri, L. jensenii, and L crispatus) for their susceptibility to tetracycline, and found their growth to be inhibited with as little as 2mg/mL of tetracycline, indicating a lack of any resistance mechanism in these strains.
Existing formats of tetracycline responsive promoters, such as those frequently utilized in the PltetO system in E. coli, do not function in Lactobacilli. This is because the architecture of promoters in Lactobacilli differ from that in E. coli, i.e. the average separation between the -35 and -10 boxes recognized by the σ70 subunit of the RNA polymerase is 17bp as opposed to 16bp, and the sequence space in this region requires more AT-rich content in Lactobacilli. The length of this spacing sequence is related to the recognizing of the -35 and -10 boxes by σ™ as consensus boxes can render very poor gene expression if they are too far apart or too close. Additionally, Lactobacillus promoters frequently contain AT-rich upstream promoter elements that can interact with a or σ factors and are thus important for robust expression. Therefore, to design a functional tetracycline response promoter for use in Lactobacilli, the promoter sequence that drives the expression of the s-layer protein A (slpA) in L acidophilus is manipulated in a manner to operably link it to tetracycline. This promoter exhibits strong, robust expression of heterologous protein in diverse species of Lactobacilli, making it an exemplary design template (A. McCracken et al. Analysis of promoter sequences from
Lactobacillus and Lactococcus and their activity in several Lactobacillus species. Arch Microbiol 2000 173:383-389).
To edit the slpA promoter sequence in order to bring it under the control of tetracycline, the tetO operator box sequence from the PltetO system was inserted into various regions within the promoter sequence. lacO and treO - the operator box sequences for trehalose and lactose based repression identified in the native Plac and Ptre promoters in L acidophilus (see Duong et al. Microb. Biotech, 4(3):357-367 (2010) hereby incorporated by reference in its entirety) were inserted into the region upstream to slpA, replacing a segment of the original sequence (preserving the original length of the operator box) at the same relative locations as they are in the wild-type, trehalose and lactose inducible promoters where the operator boxes were first characterized. Doing so resulted in Lactose and Trehalose driven induction of slpA, exceeding the performances of the original promoters. The strategy was replicated for tetracycline and various variants were tested as follows.
Variant 1: The relative locations of the tetR operators were preserved as they exist in the E. coli PltetO expression system However, a single base pair substitution was made within the tetO box downstream of the -10 sequence, in order to preserve the base encoding for the transcriptional start site (TSS) for slpA, as the tetO placement overlaps with that position (i.e., the C in the 7th base of the tetO sequences was mutated to a G) as shown in Fig. 7.
Variant 2: In this variant, the tetO boxes were inserted in locations that minimally perturb the -3S/-10, and upstream promoter sequence region. They are placed subsequent to the transcriptional start site, so that TetR protein binding physically restricts processing by RNA polymerase, rather than preventing RNA polymerase binding in the first place (as is encoded by the tetO placement in Variant 1). See Fig. 8.
Variant 3: This design mimics the relative placement of operator boxes common to carbohydrate linked induction such as lactose and trehalose. The tetO boxes are placed 5' to the "upstream promoter element" and 5' to the RBS. See Fig. 9.
Variant 4: This design combines the principles of Variants 2 and 3 together to account for a potential secondary issue. Prior literature has demonstrated that slpA owes its expression strength to the high degree of mRNA stability afforded by the 5' untranslated region of the promoter (from the TSS to the RBS), which forms a high-free-energy RNA hairpin to protect mRNA species from 5' mediated degradation. See Narita et al. Appl Microbiol Biotechnol 73:366-373 (2006). However, the hairpin is such that the RBS is in a low energy binding region of the hairpin and is thus still accessible to the ribosome. Variants 2 and 3 alter the binding free energy of the mRNA. So, to account for this property, in variant 4 there are 4 tetO boxes in this design: two that are proximal to the Transcriptional start site just as in Variant 2, and two that are proximal to the RBS as in Variant 4. However, the two near the RBS are encoded in reverse complement, evenly spaced from the first two tetO sequences next to the TSS, thus not only preserving, but increasing the mRNA hairpin folding energy (while still leaving the RBS accessible). See Fig. 10.
Fig. 11 depicts minimum free energy mRNA structural folding predictions. Each of these variants was then tested in a plasmid with no TetR (meaning the inserted promoters are not repressed, and should be constitutively active), driving a fluorescent reporter. E. coli harboring these plasmids were grown to stationary phase (where wild-type slpA promter expression is strongest), and all variants exhibited equivalent expression strength to the original promoter. Subsequently, this test was replicated in L rhamnosus GG. In this setting, only variant 2 exhibited measurable expression (3 fold-less than the wild-type promoter). Therefore, only variant 2 was selected for testing in the presence of TetR. The other variants may exhibit function in other strains of Lactobacilli, and would as such be rescreened when switching
strains. In this vein, the promoter sequence may be further edited to replace the A in the -13 position upstream of the -10 box with a G. 25% of Lactobacilli exhibit a TG dinucleotide motif in the -13/-14 positions of their promoter sequences, so when implementing the slpA promoter, or engineered variants thereof, in these strains, this nucleotide substitution may yield more robust expression. See McCracken et al. J Bacteriol 181(20):6569-6572 (1999).
The TetR coding region from PltetO was then transferred to a plasmid, fused upstream of, but in reverse complement to the promoter, so as to eliminate the potential for transcriptional read through by DNA polymerase between the two. However, no repression of the promoter was observed in Lactobacillus, due to the same reason the original PltetO promoter exhibited no function - the promoter driving expression of TetR was not sufficiently active. As such, the promoter sequence was replaced with constitutive promoters native to Lactobacilli. Selection of the promoter is important to the repressor function. Weak promoters driving low expression of TetR will result in a "leaky", basal expression in the absence of induction agent. However, TetR has high affinity to the tetO sequence, so overexpression of TetR will reduce the dynamic range of induced expression. Accordingly, the promoter for the ribosomal RNA 3-a from L. plantarum was selected, because its expression strength is S-fold weaker than that of slpA. See Fig. 12. An effective choice for the promoter of TetR is not limited to that of rRNA3-a. Published data indicate that the clpC promoter L. fermentum BR11 , the lacA promoter from L. lactis, the Idh promoter from L. plantarum, L. casei, or L. reuteri, the pgm promoter from L. agilis, and the ermB promoter from E. faecalis, all are similarly weaker than slpA, and can thus be substituted (see McCracken et al. Arch Microbiol 2000 173:383-389, Miyoshi et al., FEMS Microbiol Lett. 239(2):205-212 (2004), Lizier et al., FEMS Microbiol. Lett. 308:8-15 (2010) each of which are hereby incorporated by reference in its entirety). By extension, cognate promoters from sister species of the aforementioned organisms may similarly be used. The wild-type slpA promoter itself can also be utilized as the promoter for TetR - with the potential
benefit of maximally reducing any leakage from the induction system (basal expression in the absence of an inducer), since it is as strong or stronger than any of the engineered slpA variants. However this may require tuning in order to preserve an optimal dynamic range during induction. Slight weakening of the promoter sequence associated with TetR (referred to as TetR-slpA) via RBS site mutation,deletion or mutation of the upstream promoter element (AAATATTACAAATAGTATTTTTCGGTCA (SEQ ID NO: 20), or any subsequence thereof), or mutations introduced into the -35 box, the -10 box, or the sequence space between them, may achieve the desired strength relative to the engineered slpA promoter intended for the target protein (referred to as iZpA-target). TetR expression by slpA may also be tuned by the introduction of catabolic repressive elements such as those sensitive to glucose, to thus scale TetR expression by slpA with cellular growth rate. Alternatively, variant 2's design may be applied to TetR-slpA using mutated tetO sequences that bind with lower affinity than the original tetO (e.g. via the introduction of point mutations that break the tetO's sequence palindromes), thus scaling tetR expression with the induction by aTc itself (two candidates with weakly binding tetO mutants include TCTCTAACACTGTTAGGG (SEQ ID NO: 21) and TCTGTATCACTGATACGG (SEQ ID NO: 22), as per Bolinteneauet al. ACS /CED 59:3167- 3176 (2014) hereby incorporated by reference in its entirety). All designs take into consideration the cloning of apposed slpA promoters that is inherent to the slpA promoter sequence. In L acidophilus, the slpA promoter sequence is naturally apposed, in the same orientation as proposed for TetR-slpA, to promoter sequence for slpB. In nature, the slpA and slpB promoters invert with one another in order to control the expression of their respective proteins. The same occurs if TetR-sZpA is in apposition to ίΖρΑ-target. However, deletion of an invertase recognition site associated with the Din family of invertases (ATCTTGCTTTGAAGGGTTTTGTACAT (SEQ ID NO: 23) as per Boot et al. Mol Microbiol 21(4):799-809 (1996) hereby incorporated by reference in its entirety) located
between the transcriptional start site and the RBS, together with the introduction of a randomized DNA spacer sequence between the two promoter units (comprised of 30% A, 50% G, and 20% T), resolves this issue (see SEQ ID NO: 3). It is sufficient to delete only one of either invertase sites within TetR-slpA, or ίΖρΑ-target, though it is preferable to delete the site within TetR-slpA as this lesion disrupts the 5' untranslated region mRNA folding structure described earlier. slpA with this deletion successfully drives repressor function across a dynamic range of 106 in E. coli, when paired with slpA-tetO variant 2. See Fig. 13.
Embodiments of the present disclosure are directed to an engineered slpA promoter for repression by tetO having the following characteristics. First, for each variant, the tetO boxes can be shifted up to 22 base pairs (i.e. two Kuhn lengths) upstream or downstream from their present locations in the variants. That is, the tetO boxes can be placed within plus or minus 22 base pairs from the location identified in each variant. Second, the function of variant 2 can be readily replicated with any other promoter - since the tetO boxes are located past slpA's transcriptional start site (and regulate promoter function at the stage just after RNA polymerase binding by preventing it from proceeding into the protein reading frame), the sequence region of variant 2 from the transcriptional start site to the RBS can be fused at its 5' end to any promoter within the region of its respective transcriptional start site (see SEQ ID NO: 4, 7). Accordingly, one aspect of the present disclosure is the insertion of one or more tetO boxes within a target promoter's transcriptional start site. Such fusions are shown to either preserve or boost the expression strength of several promoters unrelated to slpA, indicating that the embodiments of the present disclosure are not limited to the promoter slpA and can be replicated for other promoters (see Miyoshi et al., FEMS Microbiol Lett. 239(2):205-212 (2004) hereby incorporated by reference in its entirety). Third, the effect of fusing slpA's 5' untranslated region to any given promoter can similarly be applied to the expression of TetR, if it is desirable to increase its expression strength, or tune its dynamic range via the
introduction of tetO sequences (or mutants thereof) as described above for TetR-slpA (exemplified with the L. fermentum BR11 ClpC promoter in SEQ ID 7). Fusing the slpA 5' untranslated region which includes one or more operator boxes to any given promoter sequence allows for methods of target nucleic acid expression or repressor expression. Fourth, the expression of TetR may be further modulated by codon engineering. Bacteria have varying tRNA abundances that lead to biased translational efficiencies within sets of degenerate codons. Thus, like codons may be substituted to tune the translational efficiency of TetR. For example, the TetR sequence may be receded with the most frequently used tRNAs in Lactobacilli to optimize translational efficiency in this species (see SEQ ID NO: S). Lastly, the principles of potential tetO (or any other repressor operator box sequence) variant design can be applied to any other promoter sequence and will be apparent to those of skill in the art based on the present disclosure.
In this expression system, gene expression was orthogonally induced with improved control. This was accomplished by engineering a high-copy plasmid that carries the tetracycline repressor (tetR) paired with the oft used PltetO system, and editing the promoter for s-layer protein A (slpA), which is one of the strongest constitutive promoters known in Lactobacilli and has been used to direct heterologous gene expression in a wide range of species (see A. McCracken et al. Analysis of promoter sequences from Lactobacillus and Lactococcus and their activity in several Lactobacillus species. Arch Microbiol 2000 173:383-389 hereby incorporated by reference in its entirety). The slpA promoter was edited by inserting tetracycline repressor protein binding sites (tetO) at a variety of locations that were then screened for function. Several guidelines were designed for promoter design in regards to the placement of tetO. Variant design was dictated by the locations of endogenous repressor binding site locations in Lactobacilli, and their endogenous catabolic repressor motifs. Custom bioinformatics were also utilized to generate consensus sequences for Lactobacillus promoters
in order to identify functionally important sequence spaces to mitigate disruption of promoter function. Lastly, promoter designs were further guided by secondary structure predictions of predicted mRNA.
EXAMPLE Π
Orthogonally Induced Gene Expression in Lactobacilli
To evaluate the functionality of the aTc induction system described herein in lactic acid bacteria, the TetR regulon described herein is driven by a L plantarum promoter paired with slpA-tetO variant 2 (current SEQ IDs 1 and 2), into L rhamnosus GG via electroporation with a high copy plasmid. Sequence verified colonies, as well as colonies harboring a negative control plasmid with no fluorescence reporter, were then picked in triplicate, and used to inoculate liquid cultures that were grown overnight. These overnight cultures were then sub- cultured 1/100 into fresh media, in duplicate - one culture containing 10 ng mL aTc, the other containing no inducing agent. The culture with inducing agent, was then serially diluted by 50%, S times (yielding cultures with S, 2.S, 1.2S, 0.62S, and 0.312S ng/mL of aTc, in addition to the original 10 ng/mL culture). These cultures were then grown to an optical density of 0.2 (to capture lag phase behavior), 0.6 (log phase), and 1.0 (stationary phase), as measured by an optical cell density meter. At each optical density, the fluorescence of all cultures and replicates were measured in absolute units in a fluorimeter. Relative fluorescence units were then computed as a fold change value over the measured fluorescence of the negative control cell cultures that were known to not express fluorescence protein.
The slpA variant featuring two tetO sites between the transcriptional start site and the ribosome binding site demonstrated reliable repression and expression of a fluorescent protein in the absence and presence of aTc, in L. rhamnosus GG - a prevalent probiotic (see FIG. 1).
Importantly, control of gene expression in all growth phases: early exponential, mid- exponential, and stationary phase were demonstrated.
The functionality of tetracycline induction was similarly demonstrated in the vaginal probiotic strain, L. gasseri, indicating the ease of transfer for this system into different strains. In this instance, the TetR regulon of the induction system was expressed by the E. faecalis ermB promoter and, as above, paired with the slpA-tetO variant 2 (current SEQ IDs 2 and 6). The experimental procedure used was exactly as described above for L. rhamnosus GG, with the exception that the dilution series began at 500 ng/mL aTc (see FIG. 14). Strong expression was driven by tetracycline with this induction system in L. gasseri, indicating the versatility of our methodology.
Under similar experimental conditions, a hybrid promoter injunction with TetR (TetR- ClpC-slpA) in L. gasseri was functional, validating the potential use of the strategy for modulating promoter function with the slpA untranslated region, as expounded in previous sections (see Fig. IS).
The functionality of the tetracycline inducible promoters as an orthogonal gene expression system can be further modified and verified in a wider array of strains and cells, and the dynamic range of the promoter can be improved by modulation of basal repression strength. According to certain aspects, methods and expression systems as herein described are provided to control production of proteins by probiotic species such as L. rhamnosus GG or L. gasseri while in vivo, which aTc has previously enabled in the gut pathogen, H. pylori, in mouse models (see A. Debowski et al. Development of a tetracycline-inducible gene expression system for the study of Helicobacter pylori pathogenesis. Appl Environ Microbiol. 2013 Dec;79(23):7351-59 hereby incorporated by reference in its entirety.
EXAMPLE ΙII
aTc-inducible Promoter Variant
According to one aspect, an aTc-inducible promoter variant is provided. According to an additional aspect, the aTc-inducible promoter variant exhibits low or undetectable levels of leakage. Lowering or preventing leakage is desirable such as in the case of controlling expression of gene editing proteins such as Cas9, where the repressed state ideally has no measurable gene editing activity. In some aspects, replacement of a regulon promoter to address leakage may not be desirable insofar as such a replacement may present incompatibility issues with the host.
According to one aspect, the present disclosure provides methods for creating lower leakage variants of an aTc-inducible promoter. According to one aspect, a promoter variant is provided wherein the sequence space around the tetO binding sites is altered. According to one aspect, a promoter variant is provided wherein the sequence space around the tetO binding sites is altered to more closely mimic the general tetO binding site sequence space as found in PltetO (which exhibits low leakage in E. coli).
According to one aspect, an altered promoter sequence is provided where the tetR binding site (or binding landing pad) includes a base pair from PltetO that is one nucleotide upstream to the first tetO binding site (SEQ ID NO: 8), the second tetO binding site (SEQ ID NO:9), or both tetO binding sites (SEQ ID NO: 10). In this manner, the promoter sequence of SEQ ID NO:2 is altered to extend the tetR binding landing pad by including one additional base pair from PltetO that is one nucleotide upstream to the first, second, or both tetO binding sites as represented in SEQ ID NO: 8, SEQ ID NO:9 and SEQ ID NO: 10. Crystallographic analysis of the TetR-tetO complex has shown that this particular nucleotide is not a critical participant in TetR binding (see J.L. Ramos et al.). For this reason, carry over of this nucleotide between PltetO and PsipA was omitted in the case of SEQ ID NO:2, in order to better preserve
the mRNA secondary structure of the 5'UTR sequence due to its influence on promoter function as described previously. However, it has been shown that substitution at this position from A T base-pairing to G/C base-pairing (as is the case in SEQ ID NO:2) renders a marginal, but measurable reduction in TetR binding affinity (A. Wissmann et al., Saturation mutagenesis of the TnlO-encoded tet operator Oi: Identification of base-pairs involved in Tet repressor recognition. /. Mol. Bio. (1988) 202:397-406). According to the present disclosure, retaining an A T base-pair results in the first tetO binding site sequence with a higher affinity to TetR, and thus a more tightly repressed system In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 8. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO:9. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 10.
According to one aspect, an altered promoter sequence is provided where the tetR binding site (or binding landing pad) includes a base pair from PltetO that is one nucleotide downstream to the first tetO binding site (SEQ ID NO: 11), the second tetO binding site (SEQ ID NO: 12), or both tetO binding sites (SEQ ID NO: 13), on its 3' end. In this manner, the promoter sequence of SEQ ID NO:2 is altered to extend the tetR binding landing pad by including one additional base pair from PltetO that is one nucleotide downstream to the first, second, or both tetO binding sites as represented in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13.
According to one aspect, the inclusion of the original nucleotide that is 1 base-pair downstream of the tetO binding site in PltetO, on its 3' end has the same effect on TetR binding
(as including the 1 base-pair upstream of the tetO binding site), as the tetO sequence is palindromic, and each of the opposite ends of the sequence exhibit the same mechanism of interaction with TetR, albeit with distinct (but identical) helix-turn-helix motifs within the TetR dimer. Carrying over this nucleotide to the first, second, or both tetO binding site sequence, and substituting the affinity-reducing G/C base-pair in that region of results in the more
repressive promoter design described by SEQ ID NO: 11, 12, and 13. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 11. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 12. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 13.
According to one aspect, an altered promoter sequence is provided that includes the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived. In this manner, the promoter sequence of SEQ ID NO:2 is altered to include the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived. The intervening 7bp sequence - currently 7bp of the original slpA 5'UTR sequence at that location - is replaced with the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived (which happens in this case to be the -35 binding site sequence of PltetO). This alteration more closely replicates the DNA helicity and melting temperature of PltetO at this location, as these factors influence the binding energy of the TetR- tetO complex. Reduction of this spacer sequence from 7 to 6 bp also serves to more closely replicate the relative rotational displacement between the tetO contact sites, which may have additional influence on TetR binding kinetics. This results in another, more repressive promoter
design variant, represented by SEQ ID NO: 14. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO: 14.
According to one aspect, a promoter sequence is provided that includes one or more or all of the following: (1) a base pair from PltetO that is one nucleotide upstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites; (2) a base pair from PltetO that is one nucleotide downstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites, on its 3' end; and/or (3) the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived. According to one aspect, a promoter sequence is provided that includes all of the following: (1) a base pair from PltetO that is one nucleotide upstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites; (2) a base pair from PltetO that is one nucleotide downstream to the first tetO binding site, the second tetO binding site, or both tetO binding sites, on its 3' end; and (3) the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived.
Relative to SEQ ID NO:2, an aspect of the present disclosure provides one or more base or base pair alterations (i.e., additions or deletions) include the following: (1) one additional base pair upstream of the first tetO binding site, (2) one additional base pair downstream of the second tetO binding site, and/or (3) replacement of the intervening, 7bp sequence - currently 7bp of the original slpA 5'UTR sequence at that location - with the 6bp sequence found in the PltetO promoter from which the tetO binding site sequences were derived (which in an exemplary emboidment is the -35 binding site sequence of PltetO). According to one aspect, the alterations are selected to more closely mimic the general tetO binding site sequence space as found in PltetO (which exhibits low leakage in E. coif)- In particular, replacement of the intervening, 7bp sequence between the tetO binding sites to its original identity serves to more
closely replicate the DNA helicity and melting temperature of PltetO at this location, as these factors influence the binding energy of the TetR-tetO complex.
An exemplary aTc-inducible slpA promoter variant is provided in SEQ ID NO: IS which includes the alterations above resulting in a combined, maximally repressive variant. In one embodiment, a promoter sequence has at least 85% homology, at least 90% homology, at least 95% homology, at least 97% homology, at least 98% homology or at least 99% homology to SEQ ID NO:15. All of the described alterations work in concert to achieve an inducible system that has essentially undetectable levels of leakage in all phases of growth. Using this aTc- inducible slpA promoter variant of SEQ ID NO: 15, no basal expression was detected in the absence of aTc, whether at stationary phase for 0 hours, 2.5 hours, 7.5 hours, and 17.5 hours, as exemplified in L. rhamnosus GG (see Fig. 16). Fig. 16 also shows an order of magnitude (10X) reduction in maximum inducible expression.
EXAMPLE 4
Induction of antibody fragment protein secretion in Lactobacillus via aTc
The engineered aTc-inducible slpA promoter has been valuable for enabling heterologous protein secretion in Lactobacillus. When secreting heterologous proteins via the Type I secretion system in Lactobacilli (or any bacterial or fungal strain), toxicity can be an issue that prevents successful secretion, especially when driving expression of a secreted protein with a strong promoter - this is because it may overload host cell secretion machinery at the expense of proteins that are naturally secreted by the same pathway that are necessary for survival. As a result, genetic engineering of expression cassettes for secreted proteins is problematic due to frame-shift mutations that prevent protein expression or secretion. This is because cells that secrete toxic levels of heterologous proteins are outcompeted by cells that
generate mutations that prevent it in culture, making it difficult to isolate cells that harbor intact genetic elements encoding the desired secretory activity.
According to one aspect, an inducible expression system is used prevent expression during bacterial culture and clone isolation. According to one aspect, expression is controlled and kept off during bacterial culture and clone isolation to avoid or lower or reduce or inhibit secretion-induced toxicity. According to one aspect, the level of a HisTagged, anti-HTV (gpl20) camelid nanobody (J3-VHH) purified from culture supernatant, when secretion of protein was driven by an inducible system (SEQ ID NO: 2) was compared to a system using an uncontrolled, constitutive slpA. Cells (in this case, L gasseri) without an expression cassette (negative control with no protein expected), an aTc-inducible expression cassette encoding J3- VHH secretion, and an equivalent, but constitutive expression cassette, were grown in culture to an optical density of 0.4 (the start of the exponential growth phase, during which time cellular protein production capacity is maximal), and split into two equal volumes - 500 ng mL of aTc was added to one, while the other received no aTc (as an internal negative control to verify functional induction). Only cells with the inducible cassette that received aTc secreted any protein into the supernatant - as shown by protein gel electrophoresis of HisTag purified L gasseri culture supernatant of Fig 17. Subsequent sequencing analysis showed that the majority of L gasseri cells that carried the constitutive expression cassette acquired mutations that stopped expression and secretion of J3-VHH, while cells with the inducible cassette remained genetically intact.
Claims
1. A lactic acid bacterial cell comprising
a first exogenous nucleic acid sequence comprising an agent-responsive element operably linked to a target nucleic acid sequence, such that the agent responsive element is inducible in the presence of the agent to initiate transcription of the target nucleic acid sequence into a corresponding mRNA and translation into a corresponding amino acid sequence.
2. The method of claim 1 wherein the agent bonds to a transcriptional repressor protein bound to a transcriptional repressor protein binding site to cause an allosteric or conformational change to the transcriptional repressor protein thereby releasing the transcriptional repressor protein from the transcriptional repressor protein binding site.
3. The lactic acid bacterial cell of claim 1 wherein the agent-responsive element comprises a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins, wherein the constitutive promoter sequence within the agent-responsive element is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins.
4. The lactic acid bacterial cell of claim 1 wherein the agent-responsive element comprises a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites and wherein the lactic acid bacterial cell further includes an exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or
more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and wherein, the agent activates the promoter and induces transcription of the target nucleic acid sequence.
5. The method of claim 1 wherein the transcriptional repressor protein binding site is TetO, the transcriptional repressor protein is TetR and the agent is tetracycline.
6. The lactic acid bacterial cell of claim 1 wherein the lactic acid bacterial cell is within the order Lactobacillales.
7. The lactic acid bacterial cell of claim 1 being a member of the group consisting of Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Carnobacterium, Enterococcus, Oenococcus, Tetragenococcus, Vagococcus, and Weisella.
8. The lactic acid bacterial cell of claim 1 wherein the lactic acid bacterial cell is a member of the group consisting of Lactobacillus acetotolerans, Lactobacillus acidifarinae, Lactobacillus acidipiscis, Lactobacillus acidophilus, Lactobacillus agilis,Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus alvei, Lactobacillus alvi, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylotrophicus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus animata, Lactobacillus antri, Lactobacillus apinorum, Lactobacillus apis, Lactobacillus apodemi, Lactobacillus aquaticus, Lactobacillus aviarius, Lactobacillus backii, Lactobacillus bifermentans, Lactobacillus bombi, Lactobacillus bombicola, Lactobacillus brantae, Lactobacillus brevis, Lactobacillus brevisimilis, Lactobacillus buchneri, Lactobacillus cacaonum, Lactobacillus camelliae, Lactobacillus capillatus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus
catenefornis, Lactobacillus ceti, Lactobacillus coleohominis, Lactobacillus colini, Lactobacillus collinoides, Lactobacillus composti, Lactobacillus concavus, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curieae, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus dextrinicus, Lactobacillus diolivorans, Lactobacillus equi, Lactobacillus equicursoris, Lactobacillus equigenerosi, Lactobacillus fabifermentans, Lactobacillus faecis, Lactobacillus faeni, Lactobacillus faiciminis, Lactobacillus fairaginis, Lactobacillus fermentum, Lactobacillus floricola, Lactobacillus florum, Lactobacillus formosensis, Lactobacillus fornicalis, Lactobacillus fructivorans, Lactobacillus frumenti, Lactobacillus fuchuensis, Lactobacillus furfuricola, Lactobacillus futsaii, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus gastricus, Lactobacillus ghanensis, Lactobacillus gigeriorum, Lactobacillus ginsenosidimutans, Lactobacillus gorillae, Lactobacillus graminis, Lactobacillus guizhouensis, Lactobacillus halophilus, Lactobacillus hammesii, Lactobacillus hamsteri, Lactobacillus harbinensis, Lactobacillus hayakitensis, Lactobacillus heilongjiangensis, Lactobacillus helsingborgensis, Lactobacillus helveticus, Lactobacillus herbarum, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus hokkaidonensis, Lactobacillus hominis, Lactobacillus homohiochii, Lactobacillus hoidei, Lactobacillus iatae, Lactobacillus iners, Lactobacillus ingluviei, Lactobacillus insectis, Lactobacillus insicii, Lactobacillus intermedius, Lactobacillus intestinalis, Lactobacillus iwatensis, Lactobacillus ixorae, Lactobacillus japonicus, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus kimbladii, Lactobacillus kimchicus, Lactobacillus kimchiensis, Lactobacillus kisonensis, Lactobacillus kitasatonis, Lactobacillus koreensis, Lactobacillus kullabergensis, Lactobacillus kunkeei, Lactobacillus larvae, Lactobacillus leichmannii, Lactobacillus letivazi, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mellifer,
Lactobacillus mellis, Lactobacillus melliventris, Lactobacillus micheneri, Lactobacillus mindensis, Lactobacillus mixtipabuli, Lactobacillus mobilis, Lactobacillus modestisalitoleians, Lactobacillus mucosae, Lactobacillus mudanjiangensis, Lactobacillus murinus, Lactobacillus nagelii, Lactobacillus namurensis, Lactobacillus nantensis, Lactobacillus nasuensis, Lactobacillus nenjiangensis, Lactobacillus nodensis, Lactobacillus odoratitofui, Lactobacillus oeni, Lactobacillus oligofermentans, Lactobacillus ori, Lactobacillus oryzae, Lactobacillus otakiensis, Lactobacillus ozensis, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus parabuchneri, Lactobacillus paracollinoides, Lactobacillus parafairaginis, Lactobacillus parakefiri, Lactobacillus paralimentarius, Lactobacillus paraplantarum, Lactobacillus pasteurii, Lactobacillus paucivorans, Lactobacillus pentosus, Lactobacillus perolens, Lactobacillus plajomi, Lactobacillus plantarum, Lactobacillus pobuzihii, Lactobacillus pontis, Lactobacillus poicinae, Lactobacillus psittaci, Lactobacillus rapi, Lactobacillus lennanquilfy, Lactobacillus rennini, Lactobacillus leuteri, Lactobacillus rhamnosus, Lactobacillus rodentium, Lactobacillus Fogosae, Lactobacillus rossiae, Lactobacillus ruminis, Lactobacillus saerimneri, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis, Lactobacillus saniviri, Lactobacillus satsumensis, Lactobacillus secaliphilus, Lactobacillus selangoiensis, Lactobacillus senioris, Lactobacillus senmaizukei, Lactobacillus sharpeae, Lactobacillus shenzhenensis, Lactobacillus sicerae, Lactobacillus silagei, Lactobacillus siliginis, Lactobacillus similis, Lactobacillus songhuajiangensis, Lactobacillus spicheri, Lactobacillus sucicola, Lactobacillus suebicus, Lactobacillus sunkii, Lactobacillus taiwanensis, Lactobacillus thailandensis, Lactobacillus tucceti, Lactobacillus ultunensis, Lactobacillus uvarum, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus vermiforme, Lactobacillus vespulae, Lactobacillus vini, Lactobacillus wasatchensis, Lactobacillus xiangfangensis, Lactobacillus yonginensis, and Lactobacillus zymae.
9. The lactic acid bacterial cell of claim 4 wherein the constitutive promoter sequence is endogenous.
10. The lactic acid bacterial cell of claim 4 wherein the constitutive promoter sequence comprises an endogenous slpA promoter sequence.
11. The lactic acid bacterial cell of claim 4 wherein the constitutive promoter sequence is an exogenous promoter sequence.
12. The lactic acid bacterial cell of claim 4 wherein the one or more repressor proteins comprise a tetracycline repressor protein (TetR).
13. The lactic acid bacterial cell of claim 4 wherein the one or more repressor proteins comprise a tetracycline repressor protein (TetR) encoded by a nucleic acid sequence having at least 85% homology to SEQ ID NO:l or a recoded variant of TetR having a least 85% homology to SEQ ID NO:5.
14. The lactic acid bacterial cell of claim 4 wherein one or more transcriptional repressor protein binding sites comprise one or more tetracycline repressor protein binding sites (tetO).
15. The lactic acid bacterial cell of claim 4 wherein the agent-responsive element comprises two tetracycline repressor protein binding sites between a transcriptional start site and a ribosome binding site.
16. The lactic acid bacterial cell of claim 4 wherein the agent-responsive element has at least 85% homology to SEQ ID NO: 2 or SEQ ID NO:4.
17. The lactic acid bacterial cell of claim 1 wherein the target nucleic acid sequence is an endogenous nucleic acid sequence or an exogenous nucleic acid sequence.
18. The lactic acid bacterial cell of claim 1 wherein the target nucleic acid sequence encodes a therapeutic protein, a diagnostic protein, a reporter gene, or an enzyme.
19. The lactic acid bacterial cell of claim 1 wherein the target nucleic acid sequence encodes an antibody.
20. The lactic acid bacterial cell of claim 1 wherein the target nucleic acid sequence encodes a Cas9 protein, Cas9 nuclease, a Cas9 nickase, a nuclease null Cas9 protein, a spCas9 nuclease, a spCas9 nickase, a nuclease null spCas9 protein, a Cpf 1 nuclease, a Cpf 1 nickase, a nuclease null Cpf 1 protein, a C2c2 nuclease, a C2c2 nickase, or a nuclease null C2c2 protein. Another nucleases with a mechanism of action similar to Cas9 might be used, as Cpf 1 nuclease, a Cpf 1 nickase or a nuclease null Cpf 1 protein.
21. The lactic acid bacterial cell of claim 1 wherein the target nucleic acid sequence encodes a fluorescent protein or a luminescent protein.
22. The lactic acid bacterial cell of claim 2 wherein the one or more repressor proteins is operatively linked to a constitutive promoter.
23. The lactic acid bacterial cell of claim 2 wherein the exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites is included in an episomal vector or integrated into cellular chromosomal DNA.
24. The lactic acid bacterial cell of claim 4 wherein the agent-responsive element is a tetracycline-responsive element comprising a plurality of tetracycline repressor protein binding sites between a transcriptional start site and a ribosome binding site.
25. The lactic acid bacterial cell of claim 1 wherein the agent-responsive element comprises a constitutive promoter sequence modified to include one or more exogenous transcriptional repressor protein binding sites corresponding to one or more transcriptional repressor proteins at one or more positions within the transcriptional start site of the constitutive promoter sequence, wherein the constitutive promoter sequence within the agent-responsive element is operable to initiate transcription of the target nucleic acid sequence in the absence of one or more transcriptional repressor proteins.
26. A vector within a lactic acid bacterial cell, wherein the vector comprises a nucleic acid sequence encoding one or more exogenous transcriptional repressor proteins corresponding to one or more exogenous transcriptional repressor protein binding sites within an endogenous promoter sequence, wherein the promoter is operably linked to a target nucleic acid sequence;
wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target
nucleic acid sequence, and wherein, tetracycline activates the promoter and induces transcription of the target nucleic acid sequence.
27. The vector of claim 26 wherein the one or more transcriptional repressor proteins comprise a tetracycline repressor protein (TetR).
28. A method of making a tetracycline inducible expression system for a target nucleic acid sequence in a lactic acid bacterial cell comprising
modifying an endogenous constitutive promoter sequence to include one or more transcriptional repressor protein binding sites, wherein the promoter sequence is operably linked to the target nucleic acid sequence;
providing to the lactic acid bacterial cell an exogenous nucleic acid sequence encoding one or more transcriptional repressor proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and wherein, tetracycline activates the promoter and induces transcription of the target nucleic acid sequence.
29. A method for controlling the expression of one or more proteins by a lactic acid bacterial cell within a subject comprising
introducing into the subject a lactic acid bacterial cell or population of lactic acid bacterial cells including (1) an endogenous constitutive promoter sequence modified to include one or more transcriptional repressor protein binding sites, wherein the promoter sequence is operably linked to one or more target nucleic acid sequences encoding the one or more proteins; and (2) exogenous nucleic acid sequence encoding one or more transcriptional repressor
proteins corresponding to the one or more transcriptional repressor protein binding sites, wherein the one or more transcriptional repressor proteins, when expressed, bind to the one or more transcriptional repressor protein binding sites to repress transcription of the target nucleic acid sequence, and,
providing the subject with a cognate binding agent which binds to the one or more transcriptional repressor proteins to activate the promoter and induce transcription of the one or more target nucleic acid sequences.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18775043.5A EP3600365A4 (en) | 2017-03-29 | 2018-03-29 | Methods of regulating gene expression in a cell |
US16/498,465 US11384358B2 (en) | 2017-03-29 | 2018-03-29 | Method of regulating gene expression in a cell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478219P | 2017-03-29 | 2017-03-29 | |
US62/478,219 | 2017-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018183685A1 true WO2018183685A1 (en) | 2018-10-04 |
Family
ID=63678315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/025154 WO2018183685A1 (en) | 2017-03-29 | 2018-03-29 | Methods of regulating gene expression in a cell |
Country Status (3)
Country | Link |
---|---|
US (1) | US11384358B2 (en) |
EP (1) | EP3600365A4 (en) |
WO (1) | WO2018183685A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020160338A1 (en) * | 2019-01-30 | 2020-08-06 | Applied Stemcell, Inc. | Controllable genome editing system |
WO2021163345A1 (en) | 2020-02-11 | 2021-08-19 | Tenza, Inc. | Bio-therapeutics for detection, diagnosis and treatment of diseases associated with mucosal bleeding |
WO2021184500A1 (en) * | 2020-03-20 | 2021-09-23 | 中国科学院动物研究所 | Recombinant expression vector capable of expressing ll-37 polypeptide, recombinant lactococcus lactis, antiviral drug, and construction method therefor and use thereof |
CN114450397A (en) * | 2019-08-01 | 2022-05-06 | 纪念斯隆-凯特琳癌症中心 | Cells and their uses for improving immunotherapy |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2360022A1 (en) * | 1999-01-08 | 2000-07-13 | Bristol-Myers Squibb Company | Prokaryotic system designed to monitor protease activity |
EP0759997B1 (en) * | 1994-05-19 | 2003-06-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of tetracycline promoter for the strictly regulated production of recombinant proteins in prokaryotic cells |
WO2004076615A2 (en) * | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
JP2006262724A (en) * | 2005-03-22 | 2006-10-05 | Kobe Univ | Protein-expressing lactic acid bacteria |
US20080131402A1 (en) * | 2005-01-25 | 2008-06-05 | Mark Farrar | Controlled Production and Delivery of Biologically Active Agents by Gut Bacteria |
US20100196956A1 (en) * | 2007-03-22 | 2010-08-05 | Bioleaders Corporation | Novel constitutive strong promoter and use thereof |
US20140044653A1 (en) * | 2012-08-07 | 2014-02-13 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
WO2016168182A1 (en) * | 2015-04-13 | 2016-10-20 | President And Fellows Of Harvard College | Production and monitoring of metabolites in cells |
US20160340665A1 (en) * | 2015-05-13 | 2016-11-24 | Synlogic, Inc. | Bacteria Engineered to Reduce Hyperphenylalaninemia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US6093394A (en) | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
WO2004007695A2 (en) | 2002-03-08 | 2004-01-22 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
WO2007019901A1 (en) | 2005-08-19 | 2007-02-22 | Unilever N.V. | Food products comprising probiotic micro-organisms and antibodies |
WO2009143309A2 (en) | 2008-05-21 | 2009-11-26 | Trustees Of Dartmouth College | Female reproductive tract and anal prophylaxes |
US20100143305A1 (en) | 2008-12-08 | 2010-06-10 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
GB2482536B (en) | 2010-08-05 | 2013-07-24 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
WO2014052438A1 (en) | 2012-09-25 | 2014-04-03 | Regents Of The University Of Minnesota | Methods for making and using antimicrobial peptides |
WO2017008018A1 (en) * | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Genetically engineered sensors for in vivo detection of bleeding |
-
2018
- 2018-03-29 US US16/498,465 patent/US11384358B2/en active Active
- 2018-03-29 EP EP18775043.5A patent/EP3600365A4/en not_active Withdrawn
- 2018-03-29 WO PCT/US2018/025154 patent/WO2018183685A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0759997B1 (en) * | 1994-05-19 | 2003-06-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of tetracycline promoter for the strictly regulated production of recombinant proteins in prokaryotic cells |
CA2360022A1 (en) * | 1999-01-08 | 2000-07-13 | Bristol-Myers Squibb Company | Prokaryotic system designed to monitor protease activity |
WO2004076615A2 (en) * | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
US20080131402A1 (en) * | 2005-01-25 | 2008-06-05 | Mark Farrar | Controlled Production and Delivery of Biologically Active Agents by Gut Bacteria |
JP2006262724A (en) * | 2005-03-22 | 2006-10-05 | Kobe Univ | Protein-expressing lactic acid bacteria |
US20100196956A1 (en) * | 2007-03-22 | 2010-08-05 | Bioleaders Corporation | Novel constitutive strong promoter and use thereof |
US20140044653A1 (en) * | 2012-08-07 | 2014-02-13 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
WO2016168182A1 (en) * | 2015-04-13 | 2016-10-20 | President And Fellows Of Harvard College | Production and monitoring of metabolites in cells |
US20160340665A1 (en) * | 2015-05-13 | 2016-11-24 | Synlogic, Inc. | Bacteria Engineered to Reduce Hyperphenylalaninemia |
Non-Patent Citations (1)
Title |
---|
See also references of EP3600365A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020160338A1 (en) * | 2019-01-30 | 2020-08-06 | Applied Stemcell, Inc. | Controllable genome editing system |
CN114450397A (en) * | 2019-08-01 | 2022-05-06 | 纪念斯隆-凯特琳癌症中心 | Cells and their uses for improving immunotherapy |
WO2021163345A1 (en) | 2020-02-11 | 2021-08-19 | Tenza, Inc. | Bio-therapeutics for detection, diagnosis and treatment of diseases associated with mucosal bleeding |
WO2021184500A1 (en) * | 2020-03-20 | 2021-09-23 | 中国科学院动物研究所 | Recombinant expression vector capable of expressing ll-37 polypeptide, recombinant lactococcus lactis, antiviral drug, and construction method therefor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US11384358B2 (en) | 2022-07-12 |
US20200109407A1 (en) | 2020-04-09 |
EP3600365A1 (en) | 2020-02-05 |
EP3600365A4 (en) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11384358B2 (en) | Method of regulating gene expression in a cell | |
Schumann | Production of recombinant proteins in Bacillus subtilis | |
Cho et al. | Engineering tools for the development of recombinant lactic acid bacteria | |
JP2009500027A (en) | Phage display using translocation simultaneously with translation of the fusion polypeptide | |
Slos et al. | Production of cholera toxin B subunit in Lactobacillus | |
de Castro et al. | Vector development timeline for mucosal vaccination and treatment of disease using Lactococcus lactis and design approaches of next generation food grade plasmids | |
Liu et al. | High-level extracellular protein expression in Bacillus subtilis by optimizing strong promoters based on the transcriptome of Bacillus subtilis and Bacillus megaterium | |
Spangler et al. | Broad range shuttle vector construction and promoter evaluation for the use of Lactobacillus plantarum WCFS1 as a microbial engineering platform | |
CN107759675A (en) | A kind of signal peptide and its application that secernment efficiency can be improved from bacillus subtilis | |
EP0677110B2 (en) | Recombinant lactic acid bacterium containing an inserted promoter | |
Suokko et al. | ClpL is essential for induction of thermotolerance and is potentially part of the HrcA regulon in Lactobacillus gasseri | |
Mayrhofer et al. | Immobilization of plasmid DNA in bacterial ghosts | |
EP0925364B1 (en) | A lactic acid bacterial regulatable expression system | |
Douillard et al. | Construction of two Lactococcus lactis expression vectors combining the Gateway and the NIsin Controlled Expression systems | |
Blanch‐Asensio et al. | Expanding the genetic programmability of Lactiplantibacillus plantarum | |
Kim et al. | Improvement of a nisin-inducible expression vector for use in lactic acid bacteria | |
CN106676125B (en) | A vector comprising a maltose promoter and a maltose promoter mutant | |
US20230381253A1 (en) | Microbes with reduced adhesion characteristics | |
Val-Calvo et al. | pLS20 is the archetype of a new family of conjugative plasmids harboured by Bacillus species | |
WO2007129087A1 (en) | Plasmid curing | |
Chae et al. | Construction of a bile-responsive expression system in Lactobacillus plantarum | |
Shkoporov et al. | Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors | |
CN107208106A (en) | Method for producing recombinant proteins by reducing rnpA gene expression | |
Lin et al. | Stable integration and expression of heterologous genes in several lactobacilli using an integration vector constructed from the integrase and attP sequences of phage ΦAT3 isolated from Lactobacillus casei ATCC 393 | |
US10898552B2 (en) | Microorganisms and methods for producing biologics and introducing biologics to sites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18775043 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018775043 Country of ref document: EP Effective date: 20191029 |